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Effects of exercise and elevated fatty acid availability on muscle lipid metabolism 




Sean Alec Newsom 
 
 
Chair: Jeffrey F. Horowitz 
 
 
Elevated systemic fatty acid availability is a key factor underlying obesity-related insulin 
resistance and type 2 diabetes.  A single session of exercise can protect against fatty acid-
induced insulin resistance, possibly via altered muscle lipid metabolism.  The overall 
purpose of this dissertation was to examine the effects of exercise and/or elevated fatty 
acid availability on the regulation of muscle lipid metabolism and changes in insulin 
sensitivity.  The major findings of my dissertation studies were as follows: In STUDY 1, 
compared with a saline infusion after exercise, an overnight (16h) lipid infusion/heparin 
infusion after a single session of exercise increased muscle triacylglycerol (TAG) 
concentration by ~30%, without any change in muscle diacylglycerol (DAG) or 
ceramide.  Despite minimal changes in activity of TAG-synthesis enzymes, greater 
membrane-associated abundance of the fatty acid transporter FAT/CD36 may have 
facilitated the enhanced muscle TAG storage.  In STUDY 2, a modest single session of 
low intensity exercise (70 min at 50% VO2peak) was sufficient to improve insulin 
sensitivity into the next day in obese adults.  Although we did not find any change in 
xii 
 
muscle lipids after exercise, reduced systemic fatty acid uptake after exercise may have 
been important for the improvement in insulin sensitivity.  Unlike STUDY 1 and STUDY 
2, which were performed in human subjects, STUDY 3 was conducted in cultured C2C12 
muscle cells, in vitro.  In STUDY 3 we found that compared with the deleterious effects 
of palmitate incubation, muscle cells acutely (12h) incubated with physiologic mixtures 
of several fatty acids showed little impairment in insulin signaling, likely due to a robust 
capacity to store the available fatty acid as TAG and accumulate virtually no DAG.  
Importantly, providing a relatively high proportion of saturated fatty acids in this fatty 
acid mixture did not abnormally affect fatty acid “partitioning” or insulin signaling.  
Together these major findings of my dissertation projects suggest that preferential storage 
of excess fatty acid as muscle TAG may limit accumulation of harmful lipid 
intermediates and protect against fatty acid-induced insulin resistance; however, the 




CHAPTER 1  
 
Statement of the Problem 
 
 
Approximately one-third of the US population is obese (11).  The burden of this epidemic 
is evidenced in part by the very high prevalence of obesity-related complications, 
including Type 2 Diabetes Mellitus (T2DM) (17).  T2DM is a chronic disease 
characterized by insulin resistance resulting in poor blood glucose regulation.  
Approximately 16.5 million people in the United States have been diagnosed with 
T2DM, and the estimated total economic cost of T2DM was nearly 160 billion dollars in 
2007 (1, 9).  Upwards of 6 million more United States adults are projected to have T2DM 
but remain undiagnosed at this time, contributing an additional estimated 18 billion 
dollars of economic burden (9, 25).  What is more alarming is that an additional 57 
million Americans, including 2 million adolescents, are considered to be pre-diabetic 
(24), many of whom will likely soon develop T2DM, adding greatly to the incidence of 
diabetes and the costs for treatment.  Even in the absence of frank T2DM, the insulin 
resistance associated with pre-diabetes is a strong predictor of many acquired chronic 
diseases such as hypertension, coronary heart disease, stroke, and certain cancers (10).  
Not surprisingly, the vast majority of pre-diabetics are obese, as obesity is considered a 
primary factor contributing to the development of insulin resistance (16-17).  Considering 
the immense economic burden and extraordinarily poor health outcomes associated with 
obesity-related insulin resistance, understanding the mechanism(s) underlying insulin 
resistance in obesity as well as the treatments for insulin resistance in obesity is of great 
importance.  
 
It is well known that excessive systemic fatty acid availability, a hallmark of obesity, can 
induce insulin resistance (2, 4-6, 14, 21-22).  Within skeletal muscle, accumulation of 




and ceramide) and subsequent activation of proinflammatory pathways (e.g., c-jun N-
terminal kinases [JNK] and nuclear factor-κB [NF-κB]) are thought to underlie obesity-
related insulin resistance (for reviews, see (13, 19)).  In short, the accumulation of fatty 
acid intermediates in skeletal muscle can occur when the excessive uptake of fat by 
myocytes is not matched by the metabolism of fatty acids within the cell (i.e., oxidation 
in the mitochondria or storage within the muscle as intramuscular triacylglycerol 
[IMTG]).  We have recently reported that performing a single session of exercise can 
prevent fatty acid-induced insulin resistance, at least in part by altering the metabolic fate 
of fatty acids within skeletal muscle (20, 22).  Specifically, increased storage of excess 
fatty acid as IMTG after exercise protected against the accumulation of fatty acid 
intermediates and proinflammatory stress (20, 22).  Despite this evidence that a single 
session of exercise may alter skeletal muscle lipid metabolism, the regulation of skeletal 
muscle lipid metabolism after exercise was still poorly understood.  Gaining a better 
understanding of the regulation of muscle lipid metabolism when fatty acid availability is 
high after exercise, as in obesity, has provide insight into potential mechanisms by which 
exercise offers protection against fatty acid-induced insulin resistance. 
 
Although it is very clear that a single session of exercise can profoundly improve insulin 
sensitivity, the minimal “dose” of exercise required to enhance insulin sensitivity the next 
day in obese adults was not known.  The few studies that had examined the influence of 
exercise intensity on blood glucose regulation in obesity not only present conflicting data, 
but also failed to directly measure insulin sensitivity (15), isolate the effects of a single 
session of exercise (3), or account for the caloric expenditure of the exercise bout (23).  It 
was clear that there is a need for a well controlled examination of the effect of exercise 
intensity on the ability of a single session of exercise to enhance insulin sensitivity in 
obese adult humans.  Furthermore, it was also important to examine putative mechanisms 
for the insulin sensitizing effects of exercise, including exercise-induced alterations in 
muscle lipid metabolism.  Whether exercise-induced alterations in muscle lipid 






Finally, evidence concerning the importance of specific fatty acid species and the role of 
saturated vs. unsaturated fatty acids in fatty acid-induced insulin resistance was 
conflicting.  Several independent studies had reported that saturated fatty acids readily 
induced insulin resistance and that unsaturated fatty acid can actually protect against 
palmitate-induced insulin resistance in vitro (7-8, 18), whereas lipid-infusion studies in 
humans report rapid induction of insulin resistance even when the lipid emulsion was 
almost entirely (~90%) composed of unsaturated fatty acids (2, 5-6, 12, 22).  Perhaps 
more importantly, it should be noted that not one of the aforementioned models of 
elevated fatty acid availability provided an accurate reflection of the elevated fatty acid 
availability common to obesity (i.e., an unbiased increase of the mixture of many 
different fatty acids comprising adipose tissue TAGs).  Determination of the effects of 
increasing fatty acid availability on muscle cell insulin signaling and lipid metabolism in 
a way that more closely resembled the elevated fatty acid availability commonly found in 
obesity (i.e., a mixture of the most abundant plasma fatty acids), yielded new insight into 
the regulation of muscle lipid metabolism and changes in muscle cell insulin signaling. 
 
My dissertation studies were designed to address the following issues:  
1) Whether increasing fatty acid availability after a single exercise session altered 
the regulation of skeletal muscle lipid metabolism the day after exercise in adult 
humans 
2) The effect of mild (50% VO2peak) and moderate (65% VO2peak) exercise 
intensity during a single session of exercise on systemic fatty acid availability, the 
accumulation of muscle lipids, and insulin sensitivity measured the next day in 
obese adults 
3) The effect of increased availability of physiologic mixtures of fatty acids on 
muscle cell insulin signaling and lipid accumulation, and whether increased fatty 
acid availability altered lipogenic, lipolytic, and/or fatty acid transport proteins in 
cultured muscle cells 
 
The overarching goal of my dissertation was to determine the effects of exercise and fatty 




knowledge outlined above were addressed through the use of both human studies and cell 
culture methodology.  Together these studies greatly aid our understanding of the 
mechanism(s) underlying insulin resistance in obesity as well as the treatments for insulin 
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Review of Literature 
 
 
The following review of literature outlines current knowledge regarding muscle lipid 
metabolism as it pertains to obesity-related insulin resistance and the role that exercise 
plays in improving insulin resistance in obesity.  This review will describe the effects of 
elevated fatty acid availability as a key mediator of obesity-related insulin resistance, 
summarize support for the role of inflammation in lipid-induced insulin resistance, and 
highlight recent studies demonstrating that acute exercise protects against lipid-induced 
insulin resistance.  Finally, specific changes in muscle lipid metabolism after exercise 
that may underlie some of the exercise-induced improvement in insulin resistance in 
obesity will be addressed. 
 
Obesity-related insulin resistance is linked with altered lipid metabolism 
Obesity is a condition characterized by excessive adiposity resulting from a chronic 
surplus of energy intake relative to energy expenditure.  Obesity is also characterized by 
elevated systemic fatty acid availability (52, 56).  Abdominally obese humans release 
fatty acid into the circulation at rates nearly two-fold greater than lean counterparts after 
an overnight fast (56).  Importantly, the excessive fatty acid availability in obesity occurs 
independently of high dietary fat intake and positive energy balance (i.e., energy intake 
exceeds energy expenditure) (52).  Chronically elevated systemic fatty acid availability 
has been linked to many obesity-related health complications (82-83).  The role of 
elevated systemic fatty acid availability in obesity-related insulin resistance will be 
discussed below. 
 
It has long been appreciated that high fatty acid availability can alter glucose metabolism 




metabolism began to take center stage as the likely mediator of insulin resistance 
associated with obesity (77-78, 100).  For the purposes of this review insulin resistance 
will be discussed in regard to dysregulated glucose metabolism, whereby there is an 
impairment in the plasma glucose lowering effects of insulin.  In this context, healthy 
insulin sensitive lean individuals become insulin resistant within as little as 3-4 hours of 
being exposed to high rates of fatty acid availability (via triacylglycerol emulsion plus 
heparin infusion) similar to that of abdominally obese individuals, thereby implicating 
elevated fatty acid availability as an important mediator of obesity-related insulin 
resistance (8, 14-15, 41, 110).  However, if elevated fatty acid availability is indeed an 
important mediator of obesity-related insulin resistance, experimental models that reduce 
fatty acid availability in obese individuals should enhance insulin sensitivity despite the 
persistence of obesity.  Nicotinic acid and the niacin derivative acipimox are potent 
inhibitors of lipolysis that can be used clinically to treat hyperlipidemia and 
experimentally to substantially lower systemic fatty acid availability.  Indeed, acute 
acipimox administration has repeatedly been shown to potently enhance insulin 
sensitivity in insulin resistant obese individuals and those with T2DM (106, 121).  Thus, 
independent of any change in obesity, per se, a reduction in systemic fatty acid 
availability is sufficient to “restore” insulin sensitivity.  Weight loss is similarly effective 
at attenuating systemic fatty acid availability and enhancing insulin sensitivity (7, 60, 
120).  In fact, our laboratory has recently reported that much of the insulin sensitizing 
effect of weight loss can be attributed to lowered systemic fatty acid availability, as 
restoration of pre-weight loss fatty acid availability (via acute lipid plus heparin infusion) 
completely reverses the effect of weight loss on insulin sensitivity (109).  From this, we 
conclude that elevated fatty acid availability is a key mediator of obesity-related insulin 
resistance.   
 
Elevated systemic fatty acid availability in obesity is paralleled by increased skeletal 
muscle fatty acid uptake (17).  Fatty acid uptake occurs largely via facilitated transport 
(16, 29), and increased skeletal muscle fatty acid transporters at the sarcolemmal 
membrane is an important contributor to the elevated rate of skeletal muscle fatty acid 




muscle is proportional to the quantity of fatty acid transporters at the cell surface 
membrane (2, 16-17).  Fatty acid translocase (FAT/CD36) is an important fatty acid 
transporter in skeletal muscle (2, 16-17, 29), and obesity is associated with increased 
membrane-associated FAT/CD36 (2, 17).  In general, there are three main metabolic fates 
for fatty acids entering the myocyte: mitochondrial β-oxidation, storage as 
triacylglycerol, or they may be partially metabolized, forming fatty acid intermediates 
(Figure 2-1).  The rate of β-oxidation of fatty acids in any myocyte is almost certainly a 
function of the energy status within the cell (i.e., ADP/ATP content), the availability of 
substrate, and the hormonal milieu.  Whether mitochondrial function or oxidative 
capacity plays a role in the rate of skeletal fatty acid oxidation will be discussed in detail 
below (see the second paragraph under the heading, A single session of exercise protects 
against lipid-induced insulin resistance).  Storage of fatty acid within skeletal muscle as 
intramyocellular triacylglycerol (IMTG) occurs through the succession of four reactions.  
The first committed step of triacylglycerol synthesis is regulated by the enzyme glycerol-
3-phosphate acyltransferase (GPAT), which catalyzes the production of lysophosphatidic 
acid (LPA) from fatty acyl-CoA and glycerol-3-phosphate.  The final key step in the 
triacylglycerol synthesis pathway is regulated by the enzyme diacylglycerol 
acyltransferase (DGAT), which catalyzes the esterification of a third fatty acyl-CoA to 
diacylglycerol (DAG) to create a triacylglycerol.  Many other lipid molecule biosynthetic 
pathways are also operating within skeletal muscle, including synthesis pathways for 
phospholipids, retinol and cholesterol esters, sphingolipids, etc.  Intermediary lipid 
molecules in the triacylglycerol pathway and several of these other synthesis pathways, 
namely long-chain acyl-CoA (LCACoA), ceramide, and diacylglycerol (DAG), herein 
globally referred to as “fatty acid intermediates,” serve as another broadly classified 
metabolic fate of skeletal muscle fatty acids.  Because skeletal muscle fatty acid uptake in 
obesity is generally believed to exceed the energetic need for fatty acid oxidation (51), 
lipid tends to accumulate such that skeletal muscle lipid content is much greater in 
sedentary obese compared with sedentary lean adults.  People with abdominal obesity 
have been reported to have high IMTG content (39, 67), such that IMTG content in obese 
individuals often two-fold greater than that of sedentary lean individuals (38, 75).  Not 




sensitivity in sedentary populations (38-39, 67, 93-94).  Importantly, evidence from our 
lab (36, 108, 110) and others (8, 38, 70, 97) indicates that elevated IMTG content is not 
causally related to insulin resistance (see the first paragraph under the heading, A single 
session of exercise protects against lipid-induced insulin resistance).  Skeletal muscle 
content of lipid intermediates such as LCACoA, ceramide, and DAG is also elevated in 
sedentary obese humans (1, 9, 53, 88, 114), again reflecting the general imbalance 
between fatty acid availability and metabolism.  It is now widely believed that the 
accumulation of lipid intermediates in skeletal muscle rather than IMTG is an important 
mediator of obesity-related insulin resistance.  How lipid accumulation in skeletal muscle 
impairs insulin sensitivity is not completely understood, however, considerable evidence 
suggests that these intermediates interfere with the insulin signaling cascade. 
 
Figure 2-1. Primary metabolic fates of fatty acids in skeletal muscle: oxidation, storage 
as intramyocellular triacylglycerol (IMTG), and formation/accumulation of fatty acid 
intermediates (e.g., long-chain acyl-CoA (LCACoA), diacylglycerol (DAG), and 
ceramide).  Perilipin proteins may act to facilitate lipid trafficking in skeletal muscle, and 
thereby may help regulate intramyocellular lipid oxidation and/or storage.  FAT/CD36, 






Lipid-induced insulin resistance is marked by inflammation and poor insulin signaling  
In skeletal muscle, insulin signaling transduction events culminate with translocation of 
glucose transporters (GLUT4) to the sarcolemmal membrane, resulting in enhanced 
glucose transport.  The major signaling events of this cascade are highlighted here, and 
also summarized in Figure 2-2.  The insulin receptor is a receptor tyrosine kinase that, 
upon insulin binding at the cell surface, autophosphorylates several cytosolic domain 
tyrosine residues and subsequently recruits and tyrosine phosphorylates adaptor insulin 
receptor substrate (IRS) proteins (89, 104, 115).  Tyrosine phosphorylated IRS proteins 
bind and activate phosphatidylinositol 3-kinase (PI3K) (22).  Activated PI3K migrates to 
the sarcolemmal phospholipid bilayer and phosphorylates PI-(4,5)-biphosphate (PIP2) to 
generate PI-(3,4,5)-triphosphate (PIP3) (122-123).  The formation of PIP3 lipids attracts 
proteins containing pleckstrin homology domains, including phophoinositide-dependent 
kinase-1 (PDK1) and Akt/protein kinase B (herein referred to as Akt) (5, 69).  PDK1 
phosphorylates Akt at Thr308, thereby activating the serine/threonine kinase (3-4), while 
phosphorylation of Akt at Ser473 by mammalian target of rapamycin complex 2 
(mTORC2) reportedly stabilizes activity of the kinase (107).  Collectively these initial 
insulin signaling events (i.e., insulin binding its receptor through induction of Akt) will 
be referred to as “proximal” insulin signaling events.  There are many known Akt targets, 
but phosphorylation of Akt Substrate of 160 kDa (AS160, or TBC1D4) appears to play 
an important role in insulin stimulated glucose transport in skeletal muscle (21, 68, 105).  
In short, it is believed that unphosphorylated AS160 acts as a brake, inhibiting GLUT4 
transporter vesicles from translocating to the cell surface (24).  In the presence of insulin, 
activated Akt phosphorylates AS160, inhibiting the Rab-GTPase-activating protein (Rab-
GAP) domain activity of the protein, thereby “releasing the brake” on Rab-dependent 
GLUT4 translocation (68, 105).  Upon GLUT4 docking and insertion into the 
sarcolemmal membrane, glucose molecules can diffuse across the cell membrane in a 
concentration dependent manner.  Importantly, far less is known about these “distal” 
insulin signaling events (i.e., downstream of Akt activation) compared with proximal 
insulin signaling.  In summary, this complex sequence of signaling events is believed to 





Figure 2-2. Major signaling events of insulin stimulated glucose uptake.  Insulin binding 
to its receptor initiates a signaling cascade involving insulin receptor substrate (IRS), 
phosphatidylinositol 3-kinase (PI3K), phosphoinositide-dependent kinase-1 (PDK1), 
mammalian target of rapamycin complex-2 (mTORC2), and Akt.  Akt phosphorylates 
AS160, inhibiting its RabGAP activity that allows subsequent Rab-dependent GLUT4 
translocation to the cell surface membrane (represented by the dashed line).  PIP2, 
phosphatidylinositol 4,5-phosphate; PIP3, phosphatidylinositol 3,4,5-phosphate. 
 
Obesity is associated with impaired insulin signaling.  These effects do not appear to be 
due to altered ability of insulin to bind its receptor, or insulin receptor 
autophosphorylation activity (43, 45, 117).  However, insulin stimulated tyrosine 
phosphorylation of IRS-1 and IRS-1-associated PI3K activity are significantly attenuated 
in obese compared with lean individuals (11, 40, 98, 117).  Additionally, artificial 
elevation of fatty acid availability in lean individuals similarly attenuates proximal 
insulin signaling (35, 42).  Despite clear evidence of impaired insulin signaling upstream 
of Akt in obesity and in models of elevated fatty acid availability, the role of impaired 
Akt activation in insulin resistance is less apparent (64-65).  Nonetheless, insulin 
stimulated phosphorylation of AS160 has been found to be reduced in skeletal muscle of 
individuals with T2DM (57).  Furthermore, these observations in insulin resistant obese 




ultimately characterized by attenuated GLUT4 abundance at the muscle cell membrane 
(45, 117).  Therefore, high fatty acid availability may be a key factor underlying impaired 
insulin signaling and GLUT4 translocation in obesity.  Importantly, these deleterious 
effects are not likely the result of excess availability of fatty acids, per se, but rather the 
intracellular accumulation of lipid intermediates. 
 
DAG and ceramide are the most well studied lipid intermediates believed to negatively 
regulate insulin signaling.  DAGs are substrate for several enzymes in skeletal muscle, 
including DGAT of the triacylglycerol synthesis pathway and DAG-kinase for the 
synthesis of phosphatidic acid, a major membrane lipid.  Genetic manipulation of these 
enzymes has been used to study the impact of altered skeletal muscle DAG content on 
insulin sensitivity.  Mice with skeletal muscle specific overexpression of DGAT1 
demonstrate increased accumulation of IMTG, low muscle DAG content, and are 
protected against high fat diet-induced insulin resistance (72).  Conversely, mice with 
DAG-kinase-δ haploinsufficiency present with increased muscle DAG content and 
muscle-specific insulin resistance (28).  These studies suggest that muscle DAG 
accumulation is likely important for the development of fatty acid-induced insulin 
resistance.  It should be noted that some DGAT1-deficient mouse models (e.g., Agouti 
yellow, AY/a) are protected against high fat diet-induced obesity and insulin resistance 
(27).  However, in this model it is likely that protection against weight gain (driven by 
altered energy balance) is at least partially responsible for protection against high fat diet-
induced insulin resistance.  Indeed, DGAT1-deficiency on a leptin-deficient background 
does not protect against weight gain, and these mice are not protected against high fat 
diet-induced insulin resistance (27).  This indicates that protection against obesity, rather 
than DGAT1 deficiency, per se, may be mediating protection against insulin resistance in 
Agouti yellow DGAT1 deficient mice.  Animal models have also been used to examine 
the role of ceramide accumulation in skeletal muscle insulin resistance.  In a seminal 
paper from the laboratory of Scott Summers (49), induction of insulin resistance in rats 
via glucocorticoid exposure (dexamethasone injection), saturated lipid infusion, or a 
genetic obesity (Zucker diabetic fatty rats) were all associated with increased skeletal 




accumulation and the onset of insulin resistance these authors showed that inhibition of 
ceramide synthesis via myriocin administration prevented both the accumulation of 
ceramide and induction of insulin resistance in skeletal muscle in each of these 
experimental models (49).  Similar findings were recently reported in a rodent model of 
high fat diet-induced insulin resistance, whereby myriocin treatment was able to prevent 
accumulation of skeletal muscle ceramide content and preserve normal insulin sensitivity 
(119). 
   
The effects of these lipid intermediates are thought to be the result of activation of several 
proinflammatory stress pathways, including protein kinase C (PKC; particularly PKCθ) 
(42, 55), inhibitor of IκB kinase (IKK)/nuclear factor-κB (NFκB) (6, 62, 113, 130), 
and/or c-Jun N-terminal kinase (JNK) (71, 92, 98).  In brief, phosphorylation of serine 
residues on IRS-1 (e.g., Ser307/312) appears to be a primary mechanism by which these 
various serine/threonine kinases inhibit insulin signaling (19, 85-86).  Serine 
phosphorylation of IRS-1 alters the ability of the protein to serve as a substrate for the 
insulin receptor, leading to reduced insulin stimulated tyrosine phosphorylation of IRS-1 
and subsequent propagation of the insulin signaling cascade (73, 81).  Indeed, high fatty 
acid availability is associated with elevated activation of these proinflammatory 
pathways, increased serine phosphorylation of IRS-1, and attenuated insulin signaling 
(40, 55, 92, 98, 117).  Furthermore, muscle-specific serine-to-alanine mutation of key 
IRS-1 residues that prevent serine phosphorylation of the protein provide protection 
against lipid-induced insulin resistance (85).  Genetic manipulation and pharmacological 
studies also provide further support for the importance of these proinflammatory 
pathways in lipid-induced insulin resistance.  Pharmacological inhibition of PKC (111) 
and knockout of PKCθ in mice (61) enhance insulin sensitivity and prevent lipid-induced 
insulin resistance.  Similarly, knockout (6) and pharmacological inhibition (37, 54, 62, 
130) of the IKK/NFκB pathway also protects against lipid-induced insulin resistance.  
Finally, both knockdown of JNK (92) and knockout of JNK-1 (47) prevent high fat diet-
induced insulin resistance.  Although discretely defined pathways of various 
proinflammatory activation via accumulation of skeletal muscle fatty acids have yet to be 




accumulation and subsequent proinflammatory activation will be very important for the 
treatment of obesity-related insulin resistance.  
 
A single session of exercise protects against lipid-induced insulin resistance 
Exercise is a cornerstone prescription for the treatment of insulin resistance.  Although 
regular exercise training potently enhances insulin sensitivity, much of the insulin 
sensitizing effect of “training” can be attributed to the most recent session(s) of exercise 
(33).  In fact, a single session of exercise is sufficient to greatly enhance insulin 
sensitivity for hours and even days in healthy lean (79, 101, 110) and obese insulin 
resistant (34) adult humans.  For the remainder of this review, the effects of only a single 
session of exercise (rather than exercise training) will be discussed unless specifically 
stated otherwise.  In addition to providing further support for the insulin sensitizing 
effects of a single session of exercise, we have recently reported that a single session of 
exercise protects against lipid-induced insulin resistance (108, 110).  In a recent study 
from our laboratory lean sedentary women performed two identical trials that differed 
only by the contents of an overnight infusion (108).  In both trials subjects performed a 
single session of aerobic exercise during the morning of day one and were subsequently 
fed an identical diet designed to replenish muscle glycogen stores and maintain energy 
balance.  During one trial, subjects received an overnight triacylglycerol plus heparin 
infusion designed to raise plasma fatty acid availability to a high physiologic level, while 
during the other trial subjects were infused with saline.  Although several previous 
studies had found insulin sensitivity to be greatly reduced in response to a similar lipid 
infusion (14-15, 35), insulin sensitivity was identical the next morning in these two trials, 
suggesting that a single session of exercise protected against fatty acid-induced insulin 
resistance.  Importantly, IMTG content was increased ~30% in response to the lipid 
infusion compared with saline.  It has been previously demonstrated that individuals with 
the greatest capacity to partition fatty acids toward IMTG synthesis have the smallest 
impairment in insulin sensitivity when fat availability is increased through either diet or 
lipid plus heparin infusion (8).  Therefore, in contrast to the previously discussed inverse 
relationship between IMTG content and insulin sensitivity in sedentary adult humans 




following a single session of exercise may limit the accumulation of harmful lipid 
intermediates known to inhibit insulin signaling, thereby providing protection against 
lipid-induced insulin resistance.  To address this hypothesis, in another recent study from 
our laboratory sedentary women were again recruited to participate in two overnight 
experimental trials.  These trials were identical other than that during one trial subjects 
remained sedentary, while during the other subjects performed a single session of 
exercise as in our previous study (110).  To determine the effects of the lipid infusion on 
the accumulation of muscle lipid intermediates and insulin sensitivity after a single 
session of exercise compared with remaining sedentary, insulin sensitivity was measured 
both during the morning of day one (before exercise) and again after overnight lipid plus 
heparin infusion the next morning.  As designed, the overnight lipid plus heparin infusion 
readily induced a ~30% reduction in insulin sensitivity when subjects remained sedentary 
(110).  Impressively, the single session of exercise not only prevented a lipid-induced 
lowering of insulin sensitivity, but significantly enhanced insulin sensitivity the next 
morning despite overnight exposure to elevated fatty acid availability.  Compared with 
remaining sedentary, muscle accumulation of DAG and ceramide was attenuated while 
IMTG content was increased nearly 50% the morning after a single session of exercise.  
Muscle GPAT1 and DGAT1 protein abundance was elevated the morning after exercise 
compared with remaining sedentary, and may have contributed to the augmented 
partitioning of fatty acids toward triacylglycerol synthesis.  Measures of skeletal muscle 
proinflammatory stress paralleled these differences in muscle lipid accumulation such 
that inflammatory activation was greatly reduced the morning after exercise compared 
with remaining sedentary (e.g., ↓pJNK and ↑IκB).  The results of these studies support 
our working hypothesis that a single session of exercise favorably alters the partitioning 
of excess fatty acids toward storage as triacylglycerol, thereby limiting excessive 
accumulation of harmful lipid intermediates that are known to inhibit insulin signaling 
via proinflammatory stress pathway activation. 
 
It has been proposed that an impaired ability to oxidize fatty acids may underlie an 
accumulation of lipid intermediates and the resultant suppression of insulin action in 




inherent or as a consequence of obesity, describes the impaired ability of skeletal muscle 
to increase fatty acid oxidation to meet the delivery of fatty acid substrate resulting in 
muscle lipid accumulation and insulin resistance.  Accordingly, several studies have 
suggested that increasing oxidative disposal of fatty acids provides important protection 
against lipid-induced insulin resistance (59, 74, 87).  While the simplistic nature of this 
theory is attractive and seemingly logical, there are fundamental flaws and contradictory 
evidence worth acknowledging.  Much of the following argument was recently well 
outlined by Dr. John Holloszy (50) and others (51), and is only briefly reviewed here.  
Most notably, the roughly 30% decrement in mitochondrial capacity observed in some 
insulin resistant populations (12, 86, 95) should have little to no effect on the ability of 
the skeletal muscle mitochondria to accommodate resting rates of fatty acid oxidation.  
Conservative estimates of maximal oxygen consumption within skeletal muscle of insulin 
resistant individuals with mitochondrial dysfunction are still 30-40 fold greater than 
resting values (50).  In this context there is little reason to suggest that even substantial 
differences in maximal mitochondrial capacity could reasonably limit resting fat 
oxidation in obesity and/or insulin resistance.  Additional evidence contrary to the notion 
that mitochondrial dysfunction underlies insulin resistance can be taken from studies of 
insulin resistant Asian Indians that exhibit higher mitochondrial capacity compared with 
insulin sensitive adults of northern European decent (90).  Furthermore, high fat feeding 
in rodents has been shown to concurrently induce mitochondrial biogenesis and insulin 
resistance (44, 118).  Finally, there is emerging evidence that decrements in 
mitochondrial capacity may in some instances present secondary to insulin resistance (18, 
48).  Therefore it is our belief that mitochondrial dysfunction, or more specifically low 
maximal mitochondrial oxidative capacity, does not underlie obesity-related insulin 
resistance.  This is not to say that fat oxidation plays no role in protecting against lipid-
induced insulin resistance.  Acute exercise is often (110, 112, 124-125), but not always 
(91), associated with a subsequent increase in resting whole-body fat oxidation.  It is 
likely that augmented oxidative disposal of fatty acids after exercise helps prevent 
accumulation of lipid intermediates within the myocyte; however, it is important to 
recognize that this change in fatty acid oxidation is likely to be quantitatively small 




mitochondrial capacity are not likely responsible for the induction of insulin resistance in 
obesity, and increased fat oxidation is not sufficient to protect against lipid-induced 
insulin resistance. 
 
It is clear that a single session of exercise is sufficient to greatly enhance insulin 
sensitivity for several hours and even into the next day in obese insulin resistant adult 
humans (34, 131), and this exercise-induced enhancement of insulin sensitivity is the 
result of increased insulin stimulated GLUT4 translocation to the cell surface membrane 
(46).  Interestingly, there is very little evidence to support a role for enhanced insulin 
signaling after a session of exercise, as most human and animal data report little to no 
change in proximal insulin signaling (i.e., upstream of Akt) after exercise (for review, see 
(23)).  Studies of obese humans are limited, but similarly suggest that acute exercise may 
not improve proximal insulin signaling despite enhanced insulin stimulated glucose 
uptake.  For example, 24 h after a single session of moderate cycle ergometer exercise 
obese insulin resistant adults demonstrated improved insulin stimulated glucose uptake 
compared with remaining sedentary, yet exhibited no change in insulin stimulated IRS1-
associated PI3K activity (30).  In contrast, some groups have reported robust 
improvements in activation of insulin signaling proteins following a single session of 
exercise.  A group of Brazilian investigators (103) has previously demonstrated that 
prolonged swim exercise (6 h) was able to completely restore normal insulin signaling 
(e.g., tyrosine phosphorylation of the insulin receptor and IRS1, serine phosphorylation 
of Akt) in skeletal muscle from high fat diet-induced obese rats incubated in a 
supraphysiological insulin concentration.  This group recently extended these findings in 
a less prolonged, yet more intense bout of weighted swim exercise, showing similarly 
effective restoration of normal insulin signaling in high fat diet-induced obese rats 
following either exercise task (31).  It is important to recognize that although these data 
are promising, these exercise protocols do not reflect practical exercise prescriptions for 
an insulin resistant human population and may not reflect in vivo human physiology.  To 
this end, the role of enhanced insulin signaling in an exercise-induced improvement in 





Regulation of muscle lipid metabolism and its relation to insulin sensitivity are poorly 
understood 
The projects of my dissertation attempt to clarify the regulation of muscle lipid 
metabolism after exercise and how this may impact insulin sensitivity. 
 
Dissertation Project I 
Our working hypothesis is that a single session of exercise protects against lipid-induced 
insulin resistance in part by favorably altering the partitioning of excess fatty acids 
toward storage as triacylglycerol.  Although it is clear that high plasma fatty acid 
availability after exercise (as in obesity) provides more substrate for IMTG synthesis, 
how elevated fatty acid availability alters the regulation of intramyocellular fatty acid 
metabolism after exercise is not completely understood.  We have previously reported 
that a single session of exercise increased skeletal muscle protein abundance of DGAT1 
and GPAT1 (110).  However, whether elevated fatty acid availability after exercise is 
associated with increased GPAT and/or DGAT enzyme activity had not been determined.  
Regulation of fatty acid flux into the myocyte to provide the necessary substrate for 
IMTG synthesis may also be important for altered fatty acid partitioning, but the effect of 
elevated fatty acid availability after exercise on myocyte fatty acid transport capacity was 
not known.  Emerging evidence indicates that IMTG accumulation as hydrophobic lipid 
droplets within the cytosol may be under the regulation of a family of proteins that are 
known to be associated with intracellular lipid droplets, now collectively referred to as 
perilipins (66).  Perilipin proteins have been suggested to be involved in the metabolic 
regulation of the triacylglycerols within the lipid droplet (e.g., storage (127, 129), 
lipolysis (20, 116), oxidation (32, 128)), as well as involved in trafficking the lipid 
droplet toward specific sites and/or signaling pathways within the cell (for review, see 
(126)).  Still, the specific roles of each of the perilipin proteins in muscle had yet to be 
completely elucidated.  For example, the improvement in insulin sensitivity during 
weight loss has been associated with increased muscle perilipin 2 relative to IMTG 
content (96); while in contrast, it has recently been reported that the improvement in 
insulin sensitivity after thiazoladinedione treatment was accompanied by a reduction in 




the putative regulators of muscle lipid triacylglycerol accumulation during conditions of 
high fatty acid availability after exercise helped to determine which of these adaptations 
may be key contributors to the improvement in insulin sensitivity found after a single 
session of exercise in obesity.  Project 1 of my dissertation determined whether elevated 
fatty acid availability alters the regulation of muscle lipid metabolism after exercise. 
 
Dissertation Project II 
The minimal “dose” of exercise required to enhance insulin sensitivity the next day in 
obese adults had not been identified.  Furthermore, whether the intensity of the exercise 
performed plays a role in exercise-induced changes in insulin sensitivity had not been 
well studied.  In what may have been the most comprehensive study regarding the effect 
of the intensity of a single session of exercise on insulin sensitivity the next day, Zhang, 
et al. (131) found that 1 h of exercise at 60% and 70%  of VO2peak significantly reduced 
the Homeostatic Model Assessment (HOMA-IR), while exercise at 40% did not.  
However, HOMA-IR provided only a very crude index of insulin resistance, and because 
they did not control for exercise energy expenditure or energy balance in their study (i.e., 
the higher the exercise intensity, the greater the negative energy balance) these data did 
not distinguish the effects of exercise, per se, from the insulin sensitizing effects of an 
energy deficit.  In contrast to these findings, 1 h of lower intensity exercise (35% of cycle 
ergometry Wmax) had been found to significantly lower 24 h glycemia compared with 
remaining sedentary in subjects with T2DM, while the modest reduction in 24 h glycemia 
following 30 min of isoenergetic exercise at a higher intensity (70% of cycle ergometry 
Wmax) did not reach statistical significance (76).  It is important to note that glycemia was 
determined by a number of factors, and cannot be interpreted as a measure of insulin 
sensitivity.  In a separate study, lower intensity exercise (40-50% VO2peak) during 8 mo 
of an exercise training program enhanced insulin sensitivity in overweight and obese 
adults to a greater degree than higher intensity exercise (65-80% VO2peak) designed to 
illicit the same total energy expenditure from exercise (10).  However, the lack of a 
measure of insulin sensitivity in the former study (76) and inability to distinguish the 
effects of “training” from the most recent session(s) of exercise in the latter study (10) 




studies in this area, it was clear that there was a need for a well controlled examination of 
the effect of exercise intensity on the ability of a single session of exercise to enhance 
insulin sensitivity in obese adult humans.  Furthermore, it was important to examine 
putative mechanisms for the insulin sensitizing effects of exercise, including exercise-
induced alterations in muscle lipid metabolism.  There had been no studies in obese adult 
humans that had examined the role of exercise intensity in altered muscle lipid 
metabolism after a single bout of exercise, and determined whether these changes relate 
to improved insulin sensitivity.  Project 2 of my dissertation determined the effect of mild 
(50% VO2peak) and moderate (65% VO2peak) exercise intensity during a single session 
of exercise on systemic fatty acid availability, the accumulation of muscle lipids, and 
insulin sensitivity measured the next day in obese adults. 
 
Dissertation Project III 
Excessive fatty acid availability, as found in obesity, impairs insulin sensitivity largely 
due to the accumulation of intramyocellular lipid intermediates.  Surprisingly little was 
known about the role of fatty acid availability on the regulation of muscle lipid 
metabolism, including the effect(s) of graded doses of fatty acid on lipid accumulation, 
the regulation of lipid metabolism, and the importance of these changes on insulin 
signaling and insulin action in muscle.  Furthermore, evidence concerning the importance 
of specific fatty acid species and the role of saturated vs. unsaturated fatty acids in fatty 
acid-induced insulin resistance was conflicting.  Several independent studies had reported 
that saturated fatty acids (i.e., palmitate) readily induced insulin resistance and that 
unsaturated fatty acid (i.e., oleate) could actually protect against palmitate-induced 
insulin resistance in vitro (25-26, 84), whereas lipid-infusion studies in humans have 
reported rapid induction of insulin resistance even when the lipid emulsion was almost 
entirely (~90%) composed of unsaturated fatty acids (8, 14-15, 41, 110).  There had been 
no explanation for these paradoxical findings in vitro compared with in vivo.  Perhaps 
more importantly, it should be noted that not one of the aforementioned models of 
elevated fatty acid availability provided an accurate reflection of the elevated fatty acid 
availability common to obesity (i.e., an unbiased increase of the mixture of many 




increasing fatty acid availability on muscle cell insulin signaling and lipid metabolism in 
a way that might more closely resemble the elevated fatty acid availability commonly 
found in obesity (i.e., a mixture of the most abundant plasma fatty acids), yielded new 
insight into the regulation of muscle lipid metabolism and changes in muscle cell insulin 
signaling.  
 
Project 3 of my dissertation was designed to determine the effect of increasing 
availability of physiologic mixtures of fatty acids on muscle cell insulin signaling and 
lipid accumulation, and to examine whether increasing fatty acid availability alters 
lipogenic, lipolytic, and/or fatty acid transport proteins in cultured muscle cells. 
Summary of Review of Literature 
The overarching goal of my dissertation was to determine the effects of exercise and fatty 
acid availability on muscle lipid metabolism and insulin sensitivity.  My working 
hypothesis was that exercise-induced alterations in skeletal muscle lipid metabolism 
provide protection against fatty acid induced (i.e., obesity-related) insulin resistance.  The 
regulation of muscle lipid metabolism during elevated fatty acid availability and in 
obesity was poorly understood.  It was not known whether the availability of fatty acid 
alters the regulation of muscle lipid metabolism after exercise, or if the intensity of an 
exercise session in an obese population differentially affected insulin sensitivity and/or 
muscle lipid metabolism.  In this context, it was unclear if altered skeletal muscle lipid 
metabolism is important for the exercise induced improvement in insulin sensitivity in 
obesity, and how these changes may mechanistically drive the improvement in insulin 
sensitivity.  It also remained to be seen how an increase in availability of a physiologic 
mixture of fatty acids influences muscle lipid metabolism and fatty acid partitioning, and 
how these responses may relate to muscle cell insulin signaling.  These gaps in 
knowledge were addressed in three separate projects.  Completion of these projects has 
enhanced our understanding of the mechanism(s) underlying insulin resistance in obesity, 
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We previously reported that a single exercise session protects against fatty acid (FA)-
induced insulin resistance, perhaps in part through augmented intramyocellular 
triacylglycerol (IMTG) synthesis.   The aim of this study was to examine the effect of 
elevated FA availability after exercise on factors regulating IMTG metabolism.  After 
exercise (90min, 65% VO2peak), 7 healthy women (body mass index: 23±1 kg/m2) were 
infused overnight (16h) with either a lipid and heparin solution (LIPID; 0.11 g fat/kg/h) 
or saline (SALINE).  We measured resting FA oxidation (indirect calorimetry) and 
obtained a skeletal muscle biopsy sample the next morning.  The 4-fold increase in 
overnight plasma FA concentration during LIPID increased IMTG by ~30% during 
LIPID vs. SALINE (49±3 vs. 38±3 μmol/g dw; P=0.04).  This was accompanied by 
~25% greater membrane-associated abundance of the FA transporter FAT/CD36 
(P<0.01), and ~8% increase in the activity of the IMTG synthesis enzyme glycerol-3-
phosphate acyltransferase (GPAT; P<0.01).   In contrast, resting FA oxidation was not 
affected. We also found no difference in the protein abundance of GPAT1 and 
diacylglycerol acyltransferase-1 (DGAT1), DGAT activity, or the abundance of the lipid 
droplet coat proteins (perilipins 2, 3, 4, 5) between treatments.  Our findings suggest 
augmented capacity for FA flux into muscle (i.e., via membrane-associated FAT/CD36), 
perhaps together with a slight, yet significant increase in activity of a key IMTG 
synthesis enzyme (GPAT) may enhance IMTG storage when FA availability is high after 
exercise.  The importance of the absence of a change in perilipin protein abundance 




Excessive fatty acid availability is a primary contributor to the insulin resistance found in 
obesity (2, 28), and we have demonstrated a single session of exercise can protect against 
fatty acid-induced insulin resistance (27, 29).  We attributed at least part of this protective 
effect of exercise to an increase in intramyocellular triacylglycerol (IMTG) synthesis for 
several hours after the exercise session (27, 29).  While it is clear that high plasma fatty 
acid availability after exercise (as in obesity) provides more substrate necessary for 
IMTG synthesis, how elevated fatty acid availability alters the regulation of 
intramyocellular fatty acid metabolism after exercise is not completely understood. 
 
The synthesis of IMTG occurs through the succession of four reactions.  The first 
committed step of this process is regulated by the enzyme glycerol-3-phosphate 
acyltransferase (GPAT), which catalyzes the production of lysophosphatidic acid (LPA) 
from fatty acyl-CoA and glycerol-3-phosphate.  The final key step in the triacylglycerol 
synthesis pathway is regulated by the enzyme diacylglycerol acyltransferase (DGAT), 
which catalyzes the esterification of a third fatty acyl-CoA to DAG to create a 
triacylglycerol.  We found that a single session of exercise was sufficient to increase the 
protein abundance of both GPAT and DGAT (29).  However, whether elevated fatty acid 
availability after exercise is associated with increased GPAT and/or DGAT enzyme 
activity remains to be determined. 
 
In addition to changes in activity of the triacylglycerol synthesis pathway enzymes, 
increased fatty acid availability may also influence other factors that can regulate IMTG 
metabolism after exercise.  Perhaps most important is the regulation of fatty acid flux into 
the myocyte, to provide the necessary substrate for IMTG synthesis.  Fatty acid 
translocase (FAT/CD36) is a principal skeletal muscle fatty acid transporter (5, 9), and 
the rate of fatty acid uptake is proportional to the abundance of FAT/CD36 on the plasma 
membrane (1, 6).  Furthermore, because IMTG accumulate largely in hydrophobic lipid 
droplets within the cytosol, regulation of IMTG metabolism may also be affected by a 
family of proteins that are known to be associated with intracellular lipid droplets (now 
collectively referred to as “perilipins” (20)).  Although the role of this family of five 
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perilipin proteins on lipid metabolism has predominantly been studied in adipocytes (for 
reviews, see (4, 33)), most of the perilipin proteins have now also been identified in 
skeletal muscle, and have been the subject of several recent studies .  However, whether 
high availability of fatty acid after exercise augments muscle fatty acid transport capacity 
(i.e., increased fatty acid transporter abundance at the muscle membrane) or the 
abundance of the perilipin proteins changes in parallel with IMTG accumulation is not 
clear.  The primary objective of this study was to determine if the accumulation of IMTG 
that we observed in response to a high availability of fatty acids after exercise (27), was 
accompanied by: 1) increased activity of key enzymes of the muscle triacylglycerol 
esterification pathway (i.e., GPAT and DGAT), 2) increased fatty acid transport capacity 
in muscle (i.e., fatty acid transporter abundance at the muscle membrane), and 3) changes 
in the abundance of perilipin proteins within skeletal muscle. 
 
Methods 
Subjects   
Seven sedentary but otherwise healthy women (age 27 ± 4 years, body mass 62.6 ± 3.7 
kg, body mass index 22.9 ± 1.0 kg/m2) volunteered to participate in this study.  Subjects 
were not taking any medications (except oral contraceptives), and all subjects underwent 
a comprehensive medical examination, including a history and physical examination, a 
12-lead electrocardiogram, and standard blood and urine tests.  All subjects were non-
smokers, weight stable (i.e., ± 2 kg), had been sedentary (regular exercise < 2 h/wk) for at 
least 6 months before the study.  Any history of metabolic or cardiovascular disease 
resulted in exclusion from participation.  All of these subjects also participated in a 
previous study in our laboratory (27).  Written, informed consent was obtained from all 
subjects before initiating participation.  All procedures of this study were approved by the 
University of Michigan Institutional Review Board.   
 
Preliminary testing   
Prior to initiating the experimental protocol, subjects underwent an incremental peak 
oxygen uptake test (VO2peak; 40.9 ± 2.3 ml/kg/min) on a stationary bicycle ergometer to 
assess aerobic fitness, and hydrostatic weighing was used to assess body composition 
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(body fat 28.7 ± 1.5 %).  This preliminary exercise test was performed at least one week 
before the subjects’ first experimental trial. 
 
Experimental protocol   
All subjects performed two experimental trials, separated by > 7 days, and all trials were 
completed during the follicular phase of the subjects’ menstrual cycle (i.e., within the 
first 2 weeks after the onset of menses).  The order of the trials was randomized, and the 
two trials differed only by the contents of the overnight infusion (see below).  The day 
before each trial, subjects received a standardized evening meal (2.25 g carbohydrate/kg, 
0.5 g  fat/kg, 0.375 g protein/kg) prepared by the Michigan Clinical Research Unit 
(MCRU) that was eaten at home and completed at 2130 h.  The next morning (Day 1) 
subjects were admitted to the MCRU at 0830 h, after an overnight fast.  Beginning at 
1000 h subjects began 90 min of exercise at ~65% VO2peak.  Exercise consisted of 45 
min of treadmill exercise, immediately followed by 45 min of exercise on a cycle 
ergometer.  Low fat meals were provided after the exercise session at 1200, 1400, and 
2030 h (total content of the three meals: 8 g carbohydrate/kg, 0.3 g fat/kg, 1.1 g 
protein/kg). Meal energy intake was calculated to match the estimated energy expenditure 
during Day 1 of each trial.  At ~1415 h two intravenous catheters were placed, one in an 
antecubital vein for use during the overnight infusion and the other in a hand vein in the 
contra-lateral arm for blood sampling.  The overnight infusion began at 1500 h and 
continued until 0700 h the next morning.  The content of this infusion was the only 
difference between the two experimental trials.  On one occasion (LIPID), subjects were 
infused overnight with a 20% lipid emulsion (Abbott Laboratories, North Chicago, IL; 
[0.55 mL/kg/h]) and heparin (Elkins-Sinn, Inc., Cherry Hill, NJ; [5 U/kg/h]) with the goal 
of increasing overnight plasma fatty acid concentration to a high physiologic level (~1.0 
mmol/L).  Because our subjects were eating a weight maintaining diet, this lipid infusion 
resulted in a total positive energy balance.  However, even when consuming a weight-
maintain diet, systemic fatty acid availability is very high in obesity.  Therefore, while an 
obese individual may be in a state of neutral energy balance (i.e., energy intake = energy 
expenditure) their systemic energy availability is very high compared with a lean person, 
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at least in part because of their high lipolytic rates.  It was the objective of our study 
design to mimic this condition.  
 
During the other trial (SALINE), subjects were infused overnight with normal saline 
(0.55 mL/kg/h).  Indeed, plasma fatty acid concentration was elevated to an overnight 
average of 0.84 ± 0.14 mmol/L during the LIPID compared with 0.22 ± 0.04 mmol/L 
during SALINE (27).  The next morning, resting oxygen consumption (VO2) and carbon 
dioxide production (VCO2) were measured (DeltaTrac, SensorMedics Inc., Yorba Linda, 
CA) at 0630 h to assess rates of substrate oxidation.  At 0900 h, a muscle biopsy was 
obtained from the vastus lateralis muscle of the thigh using the percutaneous biopsy 
technique.  Muscle biopsy samples were dissected free of adipose and connective tissue, 
rinsed in saline, dried and then frozen in liquid nitrogen.  Muscle samples were stored at -
80ºC until biochemical analysis. 
 
Analytical Procedures  
Muscle DAG and ceramide concentration 
Muscle DAG and ceramide content were assessed using the DAG-kinase assay as 
previously described (25).  In brief, lipid was extracted from ~5 mg (dry weight) of 
lyophilized muscle for each sample using a chloroform-methanol-water (1:2:0.8) 
homogenization buffer.  The reaction was carried out for 2 h at room temperature by 
adding DAG-kinase and 32P-ATP to the lipid extracts.  The reaction was stopped with 
chloroform-methanol (2:1).  The organic phase was dried, re-dissolved in 65 µl 
chloroform-methanol (2:1), and spotted for thin layer chromatography (TLC; Whatman 
Inc.). Lipids were separated in chloroform-acetone-methanol-acetic acid-water 
(100:40:20:20:10) and 32P-labelled phosphatidic acid and ceramide-1-phosphate spots 
were visualized via radiography, scraped, and counted in scintillation fluid (Tri-Carb 
2800TR, Perkin Elmer, Waltham, MA).   
 
Muscle GPAT and DGAT enzyme activity   
The enzyme activity of GPAT and DGAT were assessed in partially purified membrane 
fractions similar to as previously described (32, 37). Briefly, ~20 mg of each muscle 
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sample was homogenized in buffer solution (10 mM Tris pH 7.4, 1 mM EDTA, 1 mM 
DTT, 250 mM sucrose for GPAT and 20 mM HEPES [pH 7.4], 1 mM CaCl2, 1 mM 
DTT, 250 mM sucrose for DGAT).  A mixture of protease inhibitors was also added to 
each of the homogenization buffers.  Following a 30 min incubation, homogenates were 
centrifuged at 1500 g for 10 min at 4oC.  Pellets were discarded and the supernatants 
were centrifuged for 2 h at 38,000 rpm (> 150,000 g) at 4oC.  Supernatant was saved from 
the DGAT preparations for immunoblot analysis of cytosolic proteins (see below).  
Pellets were manually homogenized and re-dissolved in the homogenization buffer.  
Protein content of the resultant solution was measured (Pierce BCA Protein Assay, 
Thermo Scientific).  For total GPAT activity, the reaction was carried out using 10 µg 
protein in a 200 µl reaction mixture containing 75 mM Tris pH 7.5, 1 mg/ml BSA (fatty 
acid-free), 4 mM MgCl2, 1 mM DTT, 8 mM NaF, 80 µM palmitol-CoA and 414 mM 14C 
glycerol 3-phosphate (SA >20,000 dpm/nmol) for 20min at 37oC H2O bath with 
agitation. The organic phase containing 14C-labelled LPA was dried, reconstituted in 
scintillation fluid, and measured for radioactivity.  For total DGAT activity, the reaction 
was carried out using 10 µg protein in a 200µl reaction mixture containing 100 mM Tris 
pH 7.5, 250 mM sucrose, 1 mg/ml BSA (fatty acid-free), 150 mM MgCl2, 0.8 mM 
EDTA, 0.25 mM DAG, and 25 µM palmitoyl-CoA  with 0.1 µCi 14C palmitoyl-CoA (SA 
>30,000 dpm/nmol) at 37oC for 20 min in a water bath with agitation. The reaction was 
stopped with 0.75 ml chloroform-methanol (2:1).  After a 2 h room temperature lipid 
extraction, 0.375ml of 1 mM H2SO4/17 mM NaCl was added to facilitate lipid-aqueous 
phase separation. The organic phase was dried, re-dissolved in 30 µl chloroform, and 
spotted for TLC. Lipids were separated in chloroform-acetic acid (96:4) and 
triacylglycerol spots were visualized with iodine vapor, scraped, and counted in 
scintillation fluid. 
 
Western blotting  
Cytosolic and crude membrane fractions of muscle from DGAT activity preparations (see 
above) were used for immunoblot analysis of protein contents in muscle.  Proteins from 
the centrifugation supernatant of the DGAT activity preparation were concentrated using 
Amicon Ultra Centrifugal Filters (MWCO 3KD, Millipore) and used for electrophoresis 
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analysis of cytosolic proteins. 35 µg of cytosolic proteins or 25 µg of membrane proteins 
were separated by SDS-PAGE and transferred to nitrocellulose membranes.  Crude 
membrane protein fractions were used to assess GPAT1 and DGAT1 protein abundance.  
For all other immunoblot analyses, the use of cytosolic and/or membrane protein 
fractions is indicated throughout the manuscript.  Blots were probed with the following 
antibodies: α-NADH-ubiquinol oxidoreductase (COX-I; Molecular Probes, A21344), α-
FAT/CD36 (Santa Cruz Biotechnology, sc-9154), α- perilipin 1, 2, 3, and 4 (all gifts from 
P.E. Bickel and N.E. Wolins), α-perilipin 5 (American Research Products, 03-GP31), α-
GPAT1 (a gift from R.A. Coleman), and α-DGAT1 (Novus Biologicals, NB110-41487).  
Membranes were incubated with appropriate secondary antibodies and developed using 
enhanced chemiluminescence (Amersham Biosciences).  Bands were imaged and then 
quantified via densitometry (AlphaEaseFC, Alpha Innotech Corp.).  All within-subject 
comparisons were made using the same blot. 
  
Calculations 
Respiratory exchange ratio and fat oxidation 
Respiratory exchange ratio (RER) was calculated as the ratio of VCO2 to VO2.  Whole 
body fat/triacylglycerol oxidation (g/min) was calculated from VO2 and VCO2 
measurements using the equations of Frayn (15).  Whole body fatty acid oxidation was 
calculated by dividing triacylglycerol oxidation by an estimated molecular weight of 
triacylglycerol (860 g/mol) and multiplying by 3. 
 
Muscle GPAT enzyme activity  
Muscle GPAT enzyme activity was calculated as:  
   
The conversion factor of 14C glycerol 3-phosphate (G3P) was calculated by dividing the 
counts of 1μl 14C-G3P (dpm), by 14C-G3P concentration (pmol/μl).  The fraction of 14C-
G3P refers to the ratio of 14C-G3P to total G3P (mol) in the reaction mixture.  GPAT 
activity during LIPID was calculated relative to GPAT activity during SALINE, in a 




Muscle DGAT enzyme activity  
Muscle DGAT enzyme activity was calculated as:  
 
The conversion factor was calculated by dividing counts of 1μl 14C palmitoyl-CoA 
(dpm), by 14C palmitoyl-CoA concentration (pmol/μl). The fraction of 14C palmitoyl-CoA 
is the percentage of 14C palmitoyl-CoA in total palmitoyl-CoA (mol) in the reaction 
mixture.  DGAT activity during LIPID was calculated relative to DGAT activity during 
SALINE, in a within-subject manner, with the mean of these calculations be presented 
relative to one.   
 
Statistical analysis   
A paired, two-tailed Student’s t-test was used to test for significant differences in all 
outcome variables between trials.  Pearson Product Moment Correlation analysis was 
used to examine the relationship between outcome variables.  Due to limited muscle 
sample acquisition during some trials, analysis of DAG and ceramide (n = 4) and GPAT1 
protein content (n = 5) could not be performed using tissue from all subjects (n = 7).  
Statistical significance was defined as P < 0.05.  All results are presented as means ± 




We have previously reported (27) that IMTG concentration was significantly increased in 
response to elevated fatty acid availability during LIPID compared with SALINE.  In 
parallel with the marked increase in IMTG concentration, presently we found GPAT 
enzyme activity in skeletal muscle to be slightly, yet significantly greater during LIPID 
compared with SALINE (P = 0.01; Figure 3-1a).  However, the small increase in muscle 
GPAT1 protein abundance between trials did not reach statistical significance (Figure 3-
1b).  We found no differences in muscle DGAT activity or DGAT1 protein abundance 
between trials (Figure 3-2). In contrast to the elevated IMTG concentration with the lipid 
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infusion, muscle concentrations of the lipid intermediates, DAG (1839 ± 251 vs. 1494 ± 
229 pmol/mg protein for LIPID and SALINE, respectively; P = 0.35) and ceramide (665 
± 37 vs. 636 ± 72 pmol/mg protein for LIPD and SALINE, respectively; P = 0.52) were 
not different between trials. 
   
FAT/CD36 protein abundance 
The lipid infusion significantly increased membrane-associated FAT/CD36 (P = 0.005; 
Figure 3-3), while cytosolic FAT/CD36 protein content was not affected (3.7 ± 0.6 vs. 
3.8 ± 0.5 arbitrary units (AU) for LIPID and SALINE, respectively; P = 0.59).  
Interestingly, we found membrane-associated FAT/CD36 protein content to be positively 
correlated with IMTG concentration (Figure 3-4). 
   
Fatty acid oxidation 
Despite the increase in muscle membrane-associated FAT/CD36 abundance and a near 
three-fold increase in overnight plasma fatty acid concentration during LIPID compared 
with SALINE, neither RER (0.83 ± 0.02 vs. 0.81 ± 0.02, respectively, P = 0.38) nor 
whole body fatty acid oxidation (3.0 ± 0.6 vs. 3.5 ± 0.4 μmol/kg/min, respectively, P = 
0.35) were different between trials the next morning.  COX-I protein content in the 
muscle membrane fraction, an indicator of oxidative capacity, was also identical between 
trials (1.2 ± 0.2 vs. 1.2 ± 0.2 AU for LIPID and SALINE, respectively; P = 0.49). 
 
Perilipin proteins 
Perilipin 1 was not detected in muscle homogenates, indicating that our muscle samples 
were free of adipose tissue contamination (Figure 3-5a).  We did detect perilipins 2, 3, 4, 
and 5 in the skeletal muscle samples from both trials.  Interestingly, the augmented IMTG 
concentration during LIPID vs. SALINE was not accompanied by elevated 
concentrations of any of these perilipin proteins within either the cytosolic or membrane 
fractions (Figure 3-5b and 3-5c). We did not detect any perilipin 5 protein in the 






We have previously demonstrated that alterations in muscle lipid metabolism in the 
several hours after exercise can help offset insulin resistance stemming from the 
excessive fatty acid availability commonly found in obesity (27, 29).  However, the 
influence of elevated fatty acid availability on specific changes in intramyocellular lipid 
metabolism after exercise is not completely understood.  Here we found that the 
accumulation of IMTG resulting from high systemic fatty acid availability after exercise 
was accompanied by a small but significant increase in the activity of GPAT, which is a 
key regulating step in the triacylglycerol esterification pathway.  Perhaps more 
importantly, we found the lipid infusion increased the abundance of FAT/CD36 in the 
membrane fraction from skeletal muscle, suggesting that the capacity to transport fatty 
acids into the cell was enhanced.  In fact, the abundance of membrane-associated 
FAT/CD36 was significantly correlated with IMTG concentration.  Additionally, we 
found that the abundance of lipid droplet coating proteins (i.e., perilipins) was not 
increased despite the marked elevation in lipid storage within muscle.  
 
High systemic fatty acid availability after exercise is known to augment triacylglycerol 
resynthesis in muscle and elevate IMTG concentration (14, 27, 29).  Because fatty acids 
largely enter skeletal muscle via protein-mediated transport (30), the abundance of fatty 
acid transporters at the myocyte membrane largely dictates the capacity for fatty acid 
transport into the cell (1, 6).  Our finding that FAT/CD36 abundance in muscle 
membrane fractions was greater after the lipid infusion compared with saline despite no 
difference in the cytosolic fraction between trials suggests that augmented fatty acid 
likely increased the total abundance of FAT/CD36 protein, but that the additional 
FAT/CD36 was exclusively localized at the muscle membrane.  This expands on 
previous studies that have reported augmented muscle membrane FAT/CD36 in obesity 
(1, 6), by suggesting the chronic elevation in fatty acid availability found in obesity may 
be responsible for the increased abundance and altered basal localization of muscle 
FAT/CD36.  How fatty acid may be inducing this effect has yet to be determined, as 
pharmacological activation of the fatty acid ligand inducible transcription factors 
peroxisome proliferator-activated receptors (PPARs) α and γ does not augment 
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FAT/CD36 transcription in rat skeletal muscle (3), despite the known presence of a 
peroxisome proliferator response element (PPRE) in the promoter region of the 
FAT/CD36 gene (26). Because our measurement of FAT/CD36 in crude membrane 
preparations did not allow us to determine the specific localization of FAT/CD36, we do 
not have definitive evidence to support that this increased abundance of FAT/CD36 in 
our study occurred within the plasma membrane.  However, based on the previous 
finding of increased sarcolemmal FAT/CD36 protein content in obese compared with 
lean individuals (1, 6), it is likely that the lipid infusion in our study increased FAT/CD36 
within the plasma membrane.  We surmise that elevated fatty acid availability can 
increase membrane-associated FAT/CD36, thereby augmenting long-chain fatty acid 
uptake capacity into the myocyte.  The significant correlation we observed between 
membrane-associated FAT/CD36 and IMTG concentration suggests that the increased 
abundance of FAT/CD36 in the plasma membrane may be a key step in augmenting 
IMTG accumulation when circulating fatty acid availability is elevated after exercise, and 
is in agreement with other recent studies highlighting the role of FAT/CD36 in muscle 
lipid accumulation (1, 6). 
 
Accompanying the greater capacity for fatty acid flux into muscle in response to the lipid 
infusion, we also found a slight, yet significant increase in the activity of the enzyme that 
catalyzes the first committed step of the triacylglycerol synthesis pathway in muscle (i.e., 
GPAT).  Conversely, we found no effect of the lipid infusion on DGAT activity, which 
catalyzes the final step of the esterification pathway.  The relatively small increase in 
total GPAT activity that we found occurred in absence of a significant increase in GPAT1 
protein content, which could suggest that either the intrinsic activity of the enzyme was 
increased, or isoforms of GPAT other than GPAT1 were increased.  Alternatively, it is 
possible that a small increase in GPAT1 protein abundance was simply not detected with 
our immunoblotting technique, as GPAT activity was identical between trials when 
expressed relative to GPAT1 protein abundance (8.3 ± 0.4 vs. 8.3 ± 0.5 AU, 
respectively).  We previously reported that a prior session of exercise increased the 
protein abundance of both GPAT1 and DGAT1 in skeletal muscle in a similar time frame 
as in this study (29).  Because our subjects performed a session of exercise the day before 
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the muscle biopsy in both the LIPID and SALINE trials of this study, it is important to 
acknowledge that this session of exercise may have increased GPAT and DGAT protein 
abundance (and activity) during both trials compared with if no exercise had been 
performed. 
 
It has been proposed that an impaired ability to oxidize fatty acids may underlie an 
accumulation of lipid intermediates, and the resultant suppression in insulin action in 
obesity (18-19).  Accordingly, several studies have suggested that increasing oxidative 
disposal of fatty acids provides important protection against lipid-induced insulin 
resistance (19, 21).  However, whether or not fat oxidation plays a key role in the 
accumulation of intramyocellular lipids and insulin resistance in obesity is controversial 
(7, 13, 16-17).  We recently reported that in these same subjects a single session of 
exercise protected against the lipid-induced insulin resistance (27), and here we confirm 
that this protection occurred in absence of an increase in fat oxidation.  Moreover, our 
present finding that muscle DAG and ceramide concentrations were no greater after 
LIPID compared with SALINE, indicates that an increase in fatty acid oxidation is not 
required to prevent the accumulation of these lipid intermediates. Together, these data 
suggest that exercise-induced protection against lipid-induced insulin resistance is not 
dependent on an increase in fat oxidation. 
 
Intramyocellular lipids are mainly stored in lipid droplets that are coated by specialized 
proteins.  The largest family of these lipid droplet-associated proteins are now 
collectively referred to as perilipins (20).  Perilipins help establish and maintain the 
partition between insoluble triacylglycerols and the aqueous cytosol, while retaining a 
physical connection between the phases.  Perilipin proteins have been suggested to be 
involved in the metabolic regulation of the triacylglycerols within the lipid droplet (e.g., 
storage (34, 36), lipolysis (8, 31), oxidation (10, 35)), as well as involved in trafficking 
the lipid droplet toward specific sites and/or signaling pathways within the cell (for 
review, see (33)).  Still, the specific roles of each of the perilipin proteins in muscle have 
yet to be completely elucidated.  Our findings indicate that the ~30% increase in IMTG 
concentration during LIPID was not paralleled by an increased protein abundance of 
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perilipin 2, 3, 4 or 5.  This suggests that the perilipin coat surrounding the 
intramyocellular lipid droplets was less dense during LIPID compared with SALINE.  
This finding was somewhat unexpected given that the expression of perilipins 2, 4 and 5 
is known to be upregulated by PPARs α and γ (11-12). One potential functional outcome 
associated with a lower perilipin density is that with less of this protein coat, the lipid 
droplet may be more susceptible to lipase activity. However, we did not observe an 
increase in DAG concentration as one might expect if IMTG lipolytic rate was 
accelerated. The effect of changes in perilipin density on insulin sensitivity is also 
equivocal.  The improvement in insulin sensitivity during weight loss has been associated 
with increased muscle perilipin 2 relative to IMTG content (24).  In contrast, it has 
recently been reported that the improvement in insulin sensitivity after thiazoladinedione 
treatment was accompanied by a reduction in the abundance of perilipin proteins relative 
to the IMTG content (22).  Therefore, whether a change in perilipin density relative to 
IMTG content is important for the metabolic regulation of lipid storage and downstream 
effects of insulin sensitivity remains to be determined.  
 
In summary, our findings suggest that an increased fatty acid transport capacity (as 
indicated by greater membrane-associated FAT/CD36 transporter protein abundance), 
together with a slight, yet significant increase in muscle GPAT activity underlie the 
increased accumulation of IMTG when fatty acid availability is high after exercise.  
Because partitioning of fatty acids toward neutral lipid (i.e., IMTG) has been proposed to 
protect against insulin resistance (2, 27, 29), these adaptations may be key contributors to 
the improvement in insulin sensitivity found after a single session of exercise in obesity.  
However, the relatively small increase in muscle GPAT activity with no rise in DGAT 
activity during the lipid infusion, suggests that direct adaptations within the 
triacylglycerol esterification pathway may be secondary to the increase fatty acid 
transport capacity.  The significant correlation we observed between membrane-
associated FAT/CD36 and IMTG concentration does not prove causality, but helps 
support the potential impact of augmented transport capacity on IMTG synthesis.  
Additionally, our novel finding that the protein abundance of perilipin 2, 3, 4 and 5 did 
not increase in parallel with IMTG accumulation suggests that elevating fatty acid 
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availability after exercise reduced the IMTG perilipin coating density.  While changes in 
perilipin content of a lipid droplet can impact the metabolic fate of cellular lipids, the 
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Figure 3-1.  (A) Total muscle GPAT activity and (B) muscle GPAT-1 protein abundance 
the morning after the overnight infusion.  The inset figure is a representative western blot 
for two subjects.  *P<0.01 for LIPID compared with SALINE.  GPAT, glycerol-3-









Figure 3-2.  (A) Muscle DGAT activity and (B) muscle DGAT-1 protein abundance the 
morning after the overnight infusion.  The inset figures are representative western blots 
for two subjects.  DGAT, diacylglycerol acyltransferase; SAL, SALINE; LIP, LIPID; 






Figure 3-3.  Muscle membrane-associated FAT/CD36 protein abundance the morning 
after the overnight infusion.  Inset figures are representative western blots for two 







Figure 3-4.  The relationship between IMTG and membrane-associated FAT/CD36 
protein abundance the morning after the overnight infusion.  Open circles represent 
SALINE, whereas closed circles represent LIPID.  IMTG, intramyocellular 












Figure 3-5.  (A) Representative western blots from two subjects for perilipins 1, 2, 3, 4, 
and 5.  (B) Muscle protein abundance of cytosolic and (C) membrane-associated 
perilipins 2, 3, 4 and 5.  Perilipin 5 was not detected in muscle membrane preparations.  
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Improved insulin sensitivity is accompanied by reduced fatty acid uptake the day 




A single session of vigorous endurance exercise improves insulin sensitivity into the next 
day, and alterations in lipid metabolism may be important for this response.  It is not clear 
whether a relatively modest session of exercise has similar effects.  The purpose of this 
study was to determine the effect of a relatively modest session of exercise on insulin 
sensitivity and fatty acid uptake the next day in obese adults.  Eleven sedentary obese 
adults (M/F: 3/8; BMI: 37±1 kg/m2; VO2peak: 20±1 ml/kg/min) completed three 
experimental trials. On two occasions, subjects exercised to expend 350 kcals in the 
afternoon.  The next morning we measured insulin sensitivity (hyperinsulinemic-
euglycemic clamp) and whole-body fatty acid uptake (palmitate rate of disappearance 
from plasma (Rd)).  These two exercise trials were identical except for the exercise 
intensity (50% VO2peak [EX50] and 65% VO2peak [EX65]) and the duration of exercise 
necessary to expend 350 kcals (EX50= ~70min; EX65= ~55min).  Subjects also 
completed a control trial [CON], without exercise.  A relatively modest exercise session 
did indeed increase insulin sensitivity the next day, but while the 35% improvement after 
EX50 compared with CON was statistically significant (P=0.01), the 20% improvement 
after EX65 was not (P=0.17).  Interestingly, systemic fatty acid uptake tended to be lower 
(~15%, P=0.07) after EX50 compared with CON, but this effect was essentially absent 
after EX65.  Accordingly, the change in fatty acid uptake after exercise compared with 
CON was negatively correlated to the change in insulin sensitivity for all trials (r=-0.60, 
P=0.003).  In summary, a relatively modest session of exercise in obese adults improved 
insulin sensitivity the next day, and a reduction in systemic fatty acid uptake in the 
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several hours after exercise may be important for this exercise-induced improvement in 




Exercise is a cornerstone treatment for obesity-related metabolic complications, including 
insulin resistance (16), which is a primary symptom of type 2 diabetes and many other 
chronic diseases.  Importantly, much of the insulin-sensitizing effect of exercise can be 
attributed to the most recent session(s) of exercise, rather than to an accumulated effect of 
training and/or "fitness" (22, 29).  Even a single session of exercise can greatly enhance 
insulin sensitivity in insulin resistant, obese individuals (23), however, this beneficial 
effect is typically short-lived (i.e., 24-48h) (22, 29, 38).  For these reasons, we contend 
that exercise prescriptions aimed at improving insulin sensitivity in obese populations 
should be tailored to maximize the beneficial effects that occur in the several hours after 
each session of exercise. 
 
Surprisingly, the minimal "dose" of exercise required to significantly enhance insulin 
sensitivity is not known.   Devlin and Horton (23) were the first to demonstrate that a 
single session of vigorous exercise (e.g., high intensity interval exercise until fatigue) 
could significantly improve insulin sensitivity measured the next day in insulin resistant 
obese adults.  Clearly this level of strenuous exercise does not translate into a viable 
exercise prescription for most obese people, yet little is understood about the effects of a 
lower exercise stimulus (e.g., lower intensity, duration) on insulin sensitivity in obesity.  
The very few studies that have attempted to examine the metabolic benefit of less intense 
and/or shorter exercise sessions in obese subjects have yielded inconsistent results (6, 42, 
67).  The use of indirect assessments of insulin sensitivity (e.g., 24h glycemia, 
Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]), and variations in the 
control of the energy expended during the exercise sessions likely contributed to these 
equivocal findings.  The primary aim of our study was to examine the insulin sensitizing 
effects of an exercise session performed at either a rather mild intensity (50% peak 
oxygen uptake [VO2peak]) or a slightly more intense exercise session (65% VO2peak) in 
obese adults who are at risk for developing type 2 diabetes.  Importantly, the energy 
expended during exercise was identical between our two exercise treatments (350kcal), 
and these exercise sessions were far less rigorous than those previously used to 




An additional objective of this study was to examine factors that may underlie the 
improvement in insulin sensitivity in the hours after a modest session of exercise.  It has 
been clearly demonstrated that the improvement in insulin sensitivity after exercise is 
related to the exercise-induced reduction in skeletal muscle glycogen content, especially 
in lean humans (46), and animals (14).  Our laboratory has recently demonstrated that 
altered skeletal muscle lipid metabolism may also be important for the improvement in 
insulin sensitivity after exercise, particularly when systemic fatty acid availability is 
elevated (56, 58), as is commonly found in obesity (31, 34).  Specifically, our previous 
findings suggested that a single session of exercise increased fatty acid incorporation into 
triacylglycerol storage (in lean individuals exposed to an overnight lipid infusion), 
thereby limiting accumulation of fatty acid intermediates (e.g., ceramide and 
diacylglycerol [DAG]) that are known to negatively regulate insulin signaling proteins 
(15, 30, 41, 64-65).  Because obese adults are often found to have high fatty acid 
availability and uptake (31, 34), increased skeletal muscle ceramide and DAG content (3, 
33, 45, 62), and impaired skeletal muscle insulin signaling (7, 28, 51, 63), these effects of 
exercise on "fatty acid partitioning" within muscle may be particularly relevant in 
obesity.  However, the role of altered skeletal muscle lipid metabolism in the insulin 
sensitizing effect of exercise in obesity is not well understood.  Therefore, the secondary 
aim of this investigation was to evaluate the relationship between exercise-mediated 
changes in skeletal muscle lipid metabolism and alterations in insulin sensitivity after 




A total of 11 obese women and men (female/male: 8/3; BMI: 30-45 kg/m2; age: 18-45 
years; fasting blood glucose concentration: <125 mg/dl) were recruited to participate in 
study (Table 4-1).  Subjects were not taking any medications (consistent use of oral 
contraceptives was permitted), and all subjects underwent a comprehensive medical 
examination, including a history and physical examination, a 12-lead electrocardiogram, 
and standard blood and urine tests.  All subjects were non-smokers, weight stable (i.e., ± 
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2 kg for ≥ 6 months), and sedentary (exercise < 2 h/wk for ≥ 6 months).  Any history of 
metabolic or cardiovascular disease resulted in exclusion from participation.  Written, 
informed consent was obtained from all subjects before initiating participation.  All 
procedures of this study were approved by the University of Michigan Institutional 
Review Board.   
 
Preliminary testing 
At least one week before the experimental protocol, subjects performed an incremental 
peak oxygen uptake test (VO2
 
peak) on a stationary bicycle ergometer (Examiner; Lode 
B.V., Groningen, Netherlands) to assess aerobic fitness using a metabolic cart (MaxII; 
Physio-Dyne Instrument Corp., Quogue, NY).  In addition, dual energy X-ray assessment 
(DEXA; Lunar Prodigy Advance; GE Healthcare, Little Chalfont, Buckinghamshire, 
United Kingdom) was used to assess body composition.   
Experimental protocol 
All subjects participated in three separate experimental trials (i.e., two exercise trials and 
one no-exercise “control” trial; Figure 4-1).  The evening before each trial, subjects 
ingested a standardized meal at 1900h (55% carbohydrate, 30% fat, and 15% protein; 
one-third of total daily caloric requirements estimated from fat-free mass as previously 
described (18)).  The next morning (Day 1), after an overnight fast, subjects were 
admitted to the Michigan Clinical Research Unit at 0830h.  Subjects were provided a 
standardized breakfast at 0930h and lunch at 1230h (see “Study Diets” section, below).  
Because the duration of exercise varied between the two exercise trials, subjects began 
exercise at different times so that the exercise session in both trials was completed at 
1600h.  Subjects exercised at either 50% or 65% of their pre-determined VO2peak for the 
duration calculated to be required to expend 350kcal.  Energy expended during exercise 
was divided equally between treadmill and cycle ergometry exercise, with no rest 
provided between these modes of exercise.  To ensure subjects were exercising at the 
appropriate intensity and to quantify energy expenditure during exercise, we measured 
VO2 and VCO2 using a metabolic cart (Physio-Dyne Instrument Corp.) at the beginning 
of exercise and approximately every 20 min thereafter.  During the “no-exercise” trials, 
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subjects remained seated quietly.  After the exercise period (1600h), a retrograde 
intravenous catheter was placed in a hand vein for blood sampling.  Exactly 1h after 
exercise (1700h) a “meal tolerance test” was conducted by providing a standardized meal 
(20% of total daily caloric requirements; 55% carbohydrate, 30% fat, and 15% protein), 
and collecting blood samples every 15 min for 2h to measure plasma glucose and insulin 
concentrations.  Another meal was provided at 2000h and an evening snack was eaten at 
2200h (see “Study Diets” section, below).  After consumption of the evening snack a 
second intravenous catheter was placed in a forearm vein for infusions that began the 
next morning.  Subjects remained sedentary in the hospital until completion of the trial 
the next day.  
 
Beginning at 0450h the next morning, 3 blood samples were taken in 5 min intervals (i.e., 
0450h, 0455h, and 0500h) from the heated hand vein to obtain “arterialized” blood 
samples (35), for determination of background enrichment of [6,6 d2]glucose (Sigma 
Aldrich Inc., St. Louis, MO) and [1-13C]-palmitate (Cambridge Isotopes, Andover, MA).  
At 0500h we began a primed, constant rate infusion of [6,6 d2]glucose (35 µmol/kg 
priming dose; 0.41 µmol/kg/min continuous infusion).  We next measured resting energy 
expenditure (and fat oxidation) using indirect calorimetry for 30 min starting at 0700h 
(indirect calorimetry, ventilated hood; Vmax Encore; CareFusion, San Diego, CA).  At 
0730h we obtained a skeletal muscle sample (~100 mg) from the vastus lateralis.  Muscle 
biopsy samples were dissected free of adipose and connective tissue, rinsed in saline, 
blotted dry and then frozen in liquid nitrogen.  Muscle samples were stored at -80ºC until 
biochemical analysis.  At 0800h we began a constant-rate infusion of [1-13C]-palmitate 
(0.04 µmol/kg/min continuous infusion).  After 45 min of the [1-13C]-palmitate isotope 
infusion, three arterialized blood samples were obtained from a heated hand vein in 5 min 
intervals for determination of fatty acid rate of appearance (Ra) and disappearance (Rd) 
to/from the circulation [fatty acid mobilization and uptake, respectively], as well as 
determination of basal hepatic glucose production via isotope dilution of the constant rate 
infusion of [6,6 d2]glucose.  These blood samples were also analyzed for plasma 
concentrations of triacylglycerol, fatty acids, glucose, and insulin.  At 0900h we began a 
hyperinsulinemic-euglycemic clamp to assess insulin sensitivity, as described previously 
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(44).  Briefly, the clamp was performed using a constant 2h insulin infusion at a rate of 
100 mU/m2/min (21).  Plasma glucose concentration was monitored every 5 minutes 
during the clamp using a glucose autoanalyzer (Yellow Springs Instruments; Yellow 
Springs, OH), while glucose (D20 dextrose solution) was infused at a variable rate to 
maintain euglycemia.  Importantly, this glucose infusion solution was enriched with [6,6 
d2]glucose (2.5% enriched) to limit changes in glucose tracer enrichment in plasma 
during the clamp procedure (32).  In addition to the small blood samples collected every 
~5 minutes to assess plasma glucose concentration, additional plasma samples were 
collected for assessment of insulin and plasma enrichment of [6,6 d2
 
]glucose every 20 
minutes throughout the clamp, as well as in 5 min intervals during the final 20 min of the 
2h clamp.  Subjects also received an intravenous infusion of potassium (KCl) during the 
clamp to prevent hypokalemia. 
Study diets 
During the first day of each trial (Day 1), the total energy content of diet matched 
estimated daily energy expended (18).  Because the duration of exercise was different 
between trials, daily energy expenditure for each trial was estimated as:  ([((VO2 during 
exercise in L/min x 3.941) + (VCO2 during exercise in L/min x 1.11)) x (duration of 
exercise in min)] + [(1.5 x RMR) x (time not exercising in min)]).  1.5 x RMR has been 
estimated as the daily energy expenditure for healthy sedentary adults (9, 60).  Therefore, 
the subjects were in "energy balance" (i.e., energy intake = energy expenditure) during all 
trials, avoiding the confounding influence of a negative energy balance on insulin 
sensitivity (5).  Breakfast (0930h), lunch (1300h), and the post-exercise meal (1700h) 
each contained ~20% of daily energy intake.  ~30% of total daily energy requirement was 
provided at dinner (2000h), and ~10% of daily energy requirement was provided in the 
evening snack (2200h).  Although the daily energy requirements differed between the 
exercise trials compared with the no-exercise control trial, subjects ingested an identical 
snack at 2200h in all trials (i.e., identical in both absolute energy content and 
macronutrient composition).  This identical snack was designed to avoid the confounding 
influence of differences in the last meal ingested on metabolic measurements the next day 
(52).   After the snack, subjects did not eat anything until completion of the clamp 
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procedure the next day. The relative macronutrient content of the diets was 55% 
carbohydrate, 30% fat, and 15% protein (expressed as percent of total kcals), which 
represents the macronutrient content of a “typical” western diet (8).  
 
Analytical procedures 
Plasma substrate and hormone concentrations  
Plasma concentrations of glucose, fatty acid, and triacylglycerol were assessed using 
commercially available colorimetric assays (Glucose Oxidase: Thermo Fisher Scientific 
Inc., Waltham, MA; HR Series NEFA: Wako Chemicals USA, Richmond, VA; and 
Triglyceride Reagent: Sigma Aldrich Inc., 
 
St. Louis, MO).  Plasma insulin concentration 
was measured using a commercially available radioimmunoassay kit (Human Insulin-
specific RIA; Millipore, Billerica, MA). 
Plasma fatty acid kinetics and endogenous glucose production 
The tracer-to-tracee ratio (TTR) for plasma palmitate and glucose were determined by 
gas chromatography-mass spectrometry (GC/MS; Agilent 5973Networks, Mass Selective 
Detector; Agilent Technologies, Palo Alto, CA) with capillary column (50).  Proteins 
were precipitated from plasma samples with acetone, and hexane was used to extract 
plasma lipids. For palmitate analysis, fatty acids in the organic phase of the extraction 
sample were converted to their methyl esters with iodomethane and isolated using solid 
phase extraction cartridges (Suplerclean LC-Si Silica gel SPE tubes; Sigma Aldrich Inc., 
St. Louis, MO).  Electron impact ionization was used, and the mass-to-charge ratios (m/z) 
270 and 271 were selectively 
 
monitored.  For glucose analysis, the aqueous phase of the 
deproteinized plasma samples was dried overnight under vacuum.  
Hydroxylamine/pyridine solution (100 µl) was added to dried samples and heated at 
100°C for 30 min.  Acetic anhydride (75 µl) was added and samples were incubated at 
100°C for 1h, then dried under vacuum.  Samples were re-suspended in ethyl acetate (100 
µl) and masses of 187 and 189 of the penta-acetate derivative of glucose was assessed 




Muscle glycogen concentration 
Muscle biopsy samples were lyophilized at –60°C for 48h, and aliquots were weighed to 
the nearest 0.1 mg.  Muscle glycogen was determined from the measurement of glucose 
after acid hydrolysis as previously described (49).  Briefly, samples were homogenized 
and then hydrolyzed in 2N HCl, and heated at 100o
 
C for 2h.  Samples were then 
neutralized using 1N NaOH to pH 6.5-7.5 and the free glucose concentration was 
determined fluorometrically.  
Muscle triacylglycerol and diacylglycerol concentrations 
Frozen muscle (30-40 mg) was rapidly homogenized in 1.0 ml ice-cold 0.9% saline, and 
lipids then extracted overnight at 4°C in a single-phase mixture of chloroform-methanol-
aqueous homogenate (1:2:0.8, v/v/v) (10).  Internal lipid markers for triacylglycerol 
(TAG), DAG, monoacylglycerol, non-esterified fatty acid (NEFA), phospholipid (PL), 
and cholesterol ester having fatty acid moieties of odd carbon number were added at the 
start of extraction, for subsequent purity and recovery determinations (Nu-Chek Prep 
Inc., Elysian, MN; Avanti Polar Lipids Inc., Alabaster, AL). TAG, DAG and PL markers 
were each homogenous in fatty acid content (e.g., [C23:0]3-TAG).  Extraction was ended 
by addition of sufficient chloroform and saline to form two phases (2:2:1.8).  After 
vortexing and brief centrifugation, the lower chloroform phase containing lipids was 
transferred to a clean tube and dried under vacuum.  The residue was reconstituted in 100 
µl chloroform and applied to a hexane-equilibrated, aminopropyl solid phase extraction 
column.  The small chloroform volume did not significantly alter the hexane equilibrium, 
permitting virtually complete adsorption of glycerolipid and NEFA.  Individual lipid 
species were eluted using previously described solvent mixtures (11).  Column fractions 
were dried, and those containing either purified TAG or DAG were reconstituted in 100 
µl toluene.  Fatty acid methyl esters (FAMEs) were then generated via alkaline 
methanolysis, a transesterification process (11), by addition of 1.0 ml 0.2N NaOH in 
methanol having ultra-low H2O content, in order to exclude hydrolysis.  After 1h 
incubation at room temperature, the reaction was neutralized using 0.9 ml 1.0 M Na-
acetate (pH 4.75).  Chloroform (1.0 ml) was added for two-phase formation, which was 
unaffected by the small volume of toluene present.  The lower chloroform phase 
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containing FAMEs from TAG or DAG was transferred, dried and reconstituted in 
heptane.  Individual FAMEs were purified by gas chromatography with capillary column 
(Agilent Technologies).  FAMEs were detected by electron-impact mass spectrometry 
with selective ion monitoring, and quantified using FAME standards. 
 
Muscle ceramide concentration 
Analysis of skeletal muscle ceramide concentration was performed after lipid extraction 
via liquid chromatography-triple quadrupole mass spectrometry (LC-QQQ; Agilent 
Technologies 6410 Triple Quadrupole Mass Spectrometer).  In brief, samples were 
extracted by a mixture of methanol, chloroform, and water (10) supplemented with 
internal ceramide standards.  The lipid extract was dried under nitrogen gas and 
reconstituted in a 60:40 mixture of acetonitrile and isoproponal alcohol. The re-
constituted lipid extract was analyzed by electrospray ionization LC-MS/MS on a tandem 
quadrupole instrument operating in multiple reaction monitoring mode (37). Ceramides 
were identified by retention time and MS/MS fragmentation parameters, and were 
quantified relative to the closest-matching internal standard. 
 
Western blotting  
An aliquot of the initial muscle sample homogenate in 0.9% saline was taken 
immediately after homogenization (described above in Muscle triacylglycerol and 
diacylglycerol concentrations), and supplemented to achieve the final buffer solution 
(20mM Tris-HCl pH 7.5, 150mM NaCl, 2mM Na2EDTA pH 8.0, 20mM NaF, 10% (v/v) 
glycerol, 1% (v/v) NP-40, 2.5mM NaPP, 20mM β-glycerophosphate, and a mixture of 
protease inhibitors).  Samples were vortexed vigorously, then centrifuged at 20,000 g for 
10 min at 4oC.  Supernatants were collected and tested for protein concentration.  30µg 
protein was separated by SDS-PAGE (8% gels) and transferred to nitrocellulose 
membranes.  Membranes were exposed to primary antibodies against glycerol-3-
phosphate acyltransferase (GPAT1; 4613; ProSci Incorporated, Poway, CA), 
diacylglycerol acyltransferase (DGAT1; NB110-41487; Novus Biologicals, Littleton, 
CO), and DGAT2 (sc-66859; Santa Cruz Biotechnology Inc., Santa Cruz, CA) to assess 
the abundance of TAG synthesis enzymes, c-jun N-terminal kinase (JNK; 9251; Cell 
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Signaling Technology, Danvers, MA), pJNKThr183Tyr185 (4671; Cell Signaling 
Technology), phosphorylated protein kinase C (pPKCβThr641; 07-873; EMD Millipore, 
Billerica, MA), and IκBβ (9248; Cell Signaling Technology) to assess proinflammatory 
stress activation, phosphorylated insulin receptor substrate (pIRS1Ser312
 
; 2381; Cell 
Signaling Technology) to assess inhibition of insulin signaling, and nicotinamide 
phosphoribosyltransferase (NAMPT; A300-372A; Bethyl Laboratories, Inc., 
Montgomery, TX) to assess regulation of NAD-synthesis.  Membranes were then 
incubated with appropriate secondary antibodies and developed using enhanced 
chemiluminescence (GE Healthcare).  Bands of interest were imaged and then quantified 
via densitometry (AlphaEaseFC; Protein Simple, Santa Clara, CA).  All within-subject 
comparisons were made using the same blot. 
Calculations   
Energy expenditure and fat oxidation 
Energy expenditure during rest and exercise was calculated from VO2 and VCO2 
measurements using the Weir equation (43).  Whole body fat/triacylglycerol oxidation 
(g/min) was calculated from VO2 and VCO2
 
 measurements using the equations of Frayn 
(25).  Whole body fatty acid oxidation was calculated by dividing triacylglycerol 
oxidation by an estimated molecular weight of triacylglycerol (860 g/mol) and 
multiplying by 3. 
Plasma glucose and insulin area under the curve 
Area under the curve (AUC) for plasma glucose and insulin concentration curves during 
time 0-120min of the meal tolerance test was calculated using the trapezoidal rule. 
 
Hepatic glucose production 
Steady-state glucose concentration and TTR were achieved during isotope infusion; 
therefore plasma glucose Ra = Rd and could be calculated using Steele’s equation for 
steady-state conditions (61).  Exogenous glucose infusion rates were subtracted from 
glucose Ra
 




Insulin sensitivity was calculated as steady-state whole-body glucose Rd (µmol/min) over 
steady-state plasma insulin concentration (µU/mL) during the final 20 min of the clamp 
procedure.  Whole-body glucose Rd
𝐻𝑒𝑝𝑎𝑡𝑖𝑐 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = �1 −
𝐻𝐺𝑃𝑐𝑙𝑎𝑚𝑝
𝐻𝐺𝑃𝑏𝑎𝑠𝑎𝑙
� × 100 
 was calculated as the sum of the total glucose 
infusion rate (both labeled and unlabeled glucose) and hepatic glucose production during 
the final 20min of the clamp.  Hepatic insulin sensitivity was calculated from the insulin-
induced suppression of endogenous glucose production as: 
Where HGPbasal and HGPclamp
 
 (µmol/min) refer to hepatic glucose production (HGP) 
measured immediately before the clamp procedure and during the final 20 min of the 
clamp, respectively. 
Fatty acid mobilization and uptake 
Steady-state fatty acid concentration and TTR was achieved during isotope infusion; 
therefore plasma palmitate Ra = Rd and could be calculated using Steele’s equation for 
steady-state conditions (61).  Because palmitate is a reasonable marker for systemic fatty 
acid kinetics (44), total plasma fatty acid Ra/Rd were calculated by dividing plasma 
palmitate Ra/Rd
 
 by the percent contribution of palmitate to the total plasma fatty acid 
pool.   
Statistical analysis   
A repeated measures two-way (treatment x time) analysis of variance (ANOVA) was 
used to test for significant differences in plasma glucose and insulin concentrations 
during the meal tolerance test.  A repeated measures one-way ANOVA was used to test 
for significant differences in all other outcome variables between trials.  Tukey’s post hoc 
pair-wise comparisons were used to examine differences in factor means when significant 
F values were detected during ANOVA analyses.  Pearson Product Moment Correlation 
analysis was used to examine the relationship between outcome variables selected a 
priori.  Statistical significance 
 




Exercise intensity and energy expenditure 
Exercise intensity and the energy expended during exercise were successfully controlled 
in all exercise sessions as planned (Table 4-2), and all participants were able to complete 
the exercise sessions.  Because exercise intensity was greater during EX65 than EX50 
(P<0.001), subjects exercised for about 15 min longer during EX50 than EX65 (P<0.001) 
in order to successfully match exercise energy expenditure between these trials (Table 4-
2).  Compared with remaining sedentary (CON), neither resting energy expenditure (main 
effect P=0.28) nor resting fatty acid oxidation (main effect P=0.51) was different the 
morning after exercise (data not shown). 
  
Insulin sensitivity   
During the meal tolerance test performed 1h after exercise we found strong trends for 
blunted glucose and insulin responses to the meals after exercise compared with CON 
(Figure 4-2), but these attenuated responses were not statistically significant (main effects 
P=0.09 and P=0.07 for glucose AUC and insulin AUC, respectively).  Insulin sensitivity 
measured the morning after exercise using the clamp procedure was significantly 
elevated (~35%) above control levels when measured the morning after EX50 (P=0.01; 
Figure 4-3), however, the 20% increase above CON the morning after EX65 did not 
reach statistical significance (P=0.17).  There was no statistical difference in insulin 
sensitivity between EX50 and EX65 (P=0.39).  Importantly, the ability of insulin to 
suppress hepatic glucose output during the hyperinsulinemic-euglycemic clamp was 
nearly identical among trials (83±5, 88±5, and 84±7% for CON, EX50, EX65, 
respectively, main effect P=0.48), indicating that enhanced peripheral glucose 
metabolism was responsible for the exercise-induced improvement in insulin sensitivity. 
 
Plasma substrates and insulin concentration 
Exercise did not alter fasting plasma glucose, insulin, or triacylglycerol concentration the 
next morning compared with CON (Table 4-3).  However, fasting glucose Ra was 
slightly, but significantly elevated the morning after exercise during EX50 compared with 
CON (P=0.04; Figure 4-4a).  In contrast, plasma fatty acid concentration tended to be 
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lower the morning after exercise during EX50 compared with CON (main effect P=0.09; 
Table 4-3).  Accompanying this lower plasma concentration of fatty acid, fatty acid Rd 
was also ~15% lower the morning after EX50 compared with CON (Figure 4-4b), but 
this suppression in fatty acid Ra did not quite reach statistical significance (P=0.07).  
Interestingly, these effects of exercise on plasma glucose and plasma fatty acid kinetics 
were not found the morning after exercise during EX65 (Figure 4-4). 
 
Skeletal muscle glycogen and lipid content 
As expected, skeletal muscle glycogen content was lower the morning after exercise 
compared with remaining sedentary.  Glycogen concentration was significantly lower the 
morning after EX65 compared with CON (343±33 vs. 440±39 mmol/kg dry muscle; 
P=0.007).  Although muscle glycogen concentration was also relatively low the morning 
after EX50 (377±33 vs. mmol/kg dry muscle), this reduction below CON was not quite 
statistically significant (P=0.09).  There was no difference in muscle glycogen 
concentration between EX50 and EX65 (P=0.46).  In contrast to the effect of exercise on 
muscle glycogen storage, neither EX50 nor EX65 altered TAG, DAG, or ceramide 
concentrations in muscle the next morning (Figure 4-5).  Skeletal muscle protein 
expression of key TAG-synthesis enzymes GPAT1, DGAT1, and DGAT2 were also not 
different among trials (Table 4-4). 
 
Insulin signaling, pro-inflammatory markers, and NAMPT in skeletal muscle 
Although prior exercise enhanced peripheral insulin sensitivity the morning after 
exercise, phosphorylation of IRS1Ser312 in skeletal muscle, which is an indicator of 
impaired insulin signaling, was not affected by the exercise stimulus (Figure 4-6a).  In 
addition, skeletal muscle markers of proinflammatory stress including phosphorylation of 
PKCβThr641, and abundance of the NF-κB inhibitor protein IκBβ were not different among 
trials (Figure 4-6b and 4-6c).  Surprisingly, there was a strong trend for exercise to 
increase phosphorylation/activation of JNK (main effect P=0.08; Figure 4-6d), which is a 
known insulin signaling antagonist.  Finally, skeletal muscle abundance of NAMPT 




Correlation with insulin sensitivity 
We found the exercise-induced improvement in insulin sensitivity the morning after 
exercise compared with control, to be correlated with the reduction in fatty acid uptake 
(r=-0.60, P=0.003).  In addition, using data from all trials, insulin sensitivity was 
negatively correlated with fasting plasma insulin concentration (r=-0.79, P<0.001) and 
fasting plasma triacylglycerol concentration (r=-0.69, P<0.001). 
 
Discussion 
The main finding of this study was that expending only a modest amount of energy 
(350kcals) during a single session of exercise at a rather mild intensity (50% VO2peak) 
was sufficient to significantly improve insulin sensitivity at least into the next day (~19h 
after exercise) in obese adults who are at risk for developing type 2 diabetes.  
Importantly, this improvement in whole-body insulin sensitivity was due to enhanced 
peripheral glucose uptake, rather than altered hepatic glucose metabolism.  Although 
insulin sensitivity was similar the morning after exercise performed at 50%VO2peak and 
65% VO2peak, the insulin sensitizing effects of exercise of the higher intensity exercise 
session did not achieve statistical significance.  We also found that the exercise-induced 
improvement in insulin sensitivity correlated with the change in plasma fatty acid 
disappearance from plasma, suggesting that exercise-mediated alterations in fatty acid 
delivery and uptake may contribute to the improvement in insulin sensitivity after 
exercise.  A single session of exercise also tended to improve meal tolerance measured 1h 
after exercise; however, the trends for lowered plasma glucose and insulin concentrations 
after the meal did not achieve statistical significance. 
 
One of the overarching goals of this study was to determine whether a relatively modest 
exercise stimulus could have a persistent effect on insulin sensitivity into the next day in 
adults at risk for developing type 2 diabetes.  Several previous studies (23, 67) including 
some from our group (46, 58) have reported improvement in insulin sensitivity after a 
single session of vigorous and/or prolonged exercise.  However, the exercise protocols in 
all of these previous studies were very rigorous (e.g., >65% VO2peak, >1.5 h duration) 
and do not reflect realistic expectations for an exercise prescription for most sedentary 
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obese adults.  Furthermore, many of these previous studies examining the insulin 
sensitizing effect of a single session of exercise have been limited to indirect measures of 
insulin sensitivity (42, 67).  Using the “gold-standard” for assessing insulin sensitivity in 
our study (i.e., the hyperinsulinemic-euglycemic clamp), our findings indicate that even 
fairly modest exercise can significantly enhance insulin sensitivity in obese adults.  The 
exercise stimuli used in our study are generally within the current recommendations for 
physical activity provided by the American College of Sports Medicine (ACSM) (26), the 
American Heart Association (AHA) (1), and the Centers for Disease Control and 
Prevention (CDC) (2).  It is important to note that the physical activity/exercise 
recommendations from the aforementioned societies/agencies were derived with the 
primary objective of enhancing cardiovascular “fitness” accrued after weeks and months 
of regular activity.  Our findings establish that obese adults can incur metabolic benefits 
after each session of exercise, even when the exercise is relatively modest (like that 
recommended by the ACSM, AHA, and CDC), and importantly, these beneficial 
metabolic effects can clearly be attained prior to any improvement in “fitness.”  Still, it 
remains possible that even less of an exercise stimulus than that used in our study (e.g., 
lower energy expenditure/duration, etc.) may be sufficient to significantly improve 
insulin sensitivity after only a single session of exercise in sedentary obese individuals, 
and may thus present an even more attractive exercise prescription for the prevention 
and/or treatment of insulin resistance.  We are currently pursuing this exciting possibility.  
 
Moderate-to-high intensity exercise training (i.e., 65-85% VO2peak) is classically 
associated with enhanced beneficial cardiovascular and metabolic adaptations compared 
with lower intensity exercise (i.e., 40-50% VO2peak) (24).  Based on findings from 
exercise training studies, it may be logical to presume that a higher intensity of a single 
session of exercise may also evoke more potent and persistent metabolic effects in the 
hours after exercise.  Along these lines, it has been reported that 1h of exercise at 60% 
and 70% of VO2peak significantly reduced insulin resistance the next day (as measured 
by the Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]), while 
exercise at 40% VO2peak did not (67).  However, these findings must be interpreted with 
caution, in part because the researchers (67) did not control for energy balance in their 
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study (i.e., the higher the exercise intensity, the greater the exercise energy expenditure 
and subsequent negative energy balance).  Without controlling for energy balance, it is 
impossible to distinguish the effects of exercise intensity on insulin sensitivity, from the 
potent insulin sensitizing effects of a negative energy balance (5).  Interestingly, there 
have been some recent reports suggesting that lower exercise intensity may actually be 
superior to higher intensity exercise in terms of glucose regulation/control (6, 42).  For 
example, compared with remaining sedentary, 24h glycemia in type 2 diabetics was 
found to be lower (i.e., improved) during the day after 1h of low intensity exercise (35% 
of cycle ergometry Wmax), but when these same participants exercised for 30 min at 70% 
Wmax, no significant improvement in 24h glycemia was found.  It is important to note that 
24h glycemia is not an assessment of insulin sensitivity, and may be determined by a 
number of different factors (e.g., plasma glucagon, insulin, and catecholamine 
concentrations, dietary intake, etc.).  Nonetheless, this finding lends support to the 
argument that lower intensity exercise may induce metabolic benefit in the context of 
glucose control that is at least equal to, if not possibly greater than higher intensity 
exercise designed to elicit the same energy expenditure.  In a separate study, an eight 
month exercise training program requiring relatively low intensity exercise (40-50% 
VO2peak) enhanced insulin sensitivity in overweight and obese adults to a greater degree 
than participants who trained at higher exercise intensities (65-80% VO2peak) (6). 
 However, in their study (6), it was impossible to distinguish possible effects stemming 
from adaptations accrued during eight months of training from the effects of the most 
recent session(s) of exercise.  Our findings also provide support for the notion that the 
insulin sensitizing effect of a lower intensity exercise stimulus (EX50) is at least equal to 
an isoenergetic session of exercise performed at a higher intensity (EX65).  Mechanisms 
underlying the possibility of a more robust beneficial metabolic response after mild 
compared with higher exercise intensity have not been well studied.  Because our study 
was designed to match the energy expended during exercise, this required the participants 
to exercise ~15 minutes longer during EX50 compared with EX65.  Therefore, we cannot 
rule out the possibility that something associated with a longer duration of exercise may 
have influenced the metabolic responses (even though energy expenditure was identical), 
but what may cause a possible beneficial effect of exercise duration is not clear.  We 
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must also reemphasize that despite the fact that the improvement in insulin sensitivity 
after EX65 did not achieve statistical significance compared with remaining sedentary, 
we are confident that the insulin sensitizing effect of this exercise stimulus is fairly 
similar to that of EX50.  As shown in Figure 4-7, insulin sensitivity values measured in 
response to both exercise stimuli were highly correlated and yield a linear regression 
equation with a slope near 1 and a y-intercept near 0, indicating that insulin sensitivity 
values measured the morning after EX50 and EX65 were indeed similar.  Furthermore, it 
is noteworthy that insulin sensitivity values measured in response to exercise were similar 
between women and men. 
 
Because hepatic glucose production during steady-state of the hyperinsulinemic-
euglycemic clamp was nearly identical among all of our experimental trials, the 
improvement in whole-body insulin sensitivity after exercise was not due to changes in 
the liver, but instead due to enhanced peripheral glucose metabolism.  It is likely that 
much if not all of this effect was driven by improved glucose metabolism within skeletal 
muscle (20).  Muscle glycogen is known to be a key mediator of the improvement in 
insulin sensitivity after exercise (14, 46).  The magnitude of the improvement in insulin 
sensitivity in the hours after exercise has generally been found to be inversely-related to 
the exercise-induced reduction in muscle glycogen content (12).  As anticipated, muscle 
glycogen concentration was lowest the day after exercise performed at our higher 
exercise intensity (EX65).  However, it was unexpected that the exercise-induced 
improvement in insulin sensitivity did not more closely parallel changes in skeletal 
muscle glycogen content (i.e., the lowest muscle glycogen after EX65 was not 
accompanied by the greatest insulin sensitivity).  The reason for this is not known, but 
one possibility may be that higher intensity exercise may have acutely activated a greater 
pro-inflammatory/stress response in skeletal muscle (4), which may counteract the insulin 
sensitizing effects of a lower muscle glycogen concentration in our participants (39, 47, 
51).  Indeed, we found a strong trend for exercise to increase the phosphorylation of the 
highly responsive stress-related kinase JNK in skeletal muscle, and this effect appeared to 
be greatest during EX65.  The trend for an increase in JNK phosphorylation after exercise 
is somewhat in contrast to previous work from our laboratory, where we reported that a 
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single session of exercise attenuated JNK phosphorylation in lean subjects who were 
exposed to an overnight lipid infusion (58).  However, in our earlier study (58) we only 
measured JNK phosphorylation while our subjects were being infused with an exogenous 
lipid emulsion for several hours, which may have been confounding.  Our present 
observation that exercise tended to increase skeletal muscle NAMPT abundance during 
EX50 may have also contributed to the significant increase in insulin sensitivity we found 
after exercise at this rather mild intensity.  NAMPT catalyzes a critical step in the 
biosynthesis of nicotinamide adenine dinucleotide (NAD), which is a key activator of 
Sirtuin1 (Sirt1); a deacetylase considered to be a putative regulator of skeletal muscle 
insulin sensitivity (59).  It remains to be determined whether augmented skeletal muscle 
NAMPT abundance and/or increased Sirtuin activity are important for the insulin 
sensitizing effect of exercise, but the topic appears to be gaining attention (17, 48, 54).  
 
We (57) and others (55, 66) have previously reported systemic fatty acid mobilization 
and uptake to be a primary determinant of whole-body insulin sensitivity, particularly in 
obesity-related insulin resistance.  In keeping with this hypothesis, here we found the 
change in insulin sensitivity after exercise compared with control to be correlated with 
the change in plasma fatty acid rate of disappearance.  Although causality cannot be 
inferred from this correlation, this finding supports the notion that an exercise-induced 
reduction in fatty acid uptake may be an important mediator of the insulin sensitizing 
effect of exercise in obese individuals.  One seemingly important beneficial effect of a 
lower fatty acid uptake is that less intracellular substrate is available for ectopic lipid 
synthesis in skeletal muscle, thereby limiting the accumulation of lipid intermediates, like 
diacylglycerol and ceramide that have been linked with suppressed insulin action (15, 30, 
41, 64-65).  In addition to simply lowering the uptake of fatty acids, previous findings 
from our lab suggest that exercise-mediated changes within skeletal muscle may alter 
how the fatty acids are “partitioned” within the myocyte; facilitating storage as 
triacylglycerol, which may also reduce the available substrate for synthesis of some lipid 
intermediates known to impair insulin signaling (STUDY 1) and (58).  However, unlike 
our previous work (56, 58), in the present study we were unable to detect any changes in 
skeletal muscle lipid content or protein abundance of key lipid synthesizing enzymes 
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after either of the exercise trials compared with control.  These discrepancies between our 
current and previous findings may be partly explained by the difference in subject 
population used (i.e., obese vs. lean).  For example, the high skeletal muscle lipid content 
commonly observed in obese individuals (27, 40), may limit the ability to detect what 
might be relatively subtle (but potentially important) changes in muscle lipid content after 
exercise.  Quantitative measurement of what is really still a relatively small amount of 
lipid in skeletal muscle tissue is known to be difficult, with sensitivity being dependent 
upon the method of measurement used (19).  However, mass spectrometry technology 
(employed in this study) appears to provide a sensitive method for assessing skeletal 
muscle lipids.  It is also noteworthy that the vastus lateralis muscle is not highly recruited 
during low-speed level treadmill walking activity (representing half of the exercise 
stimulus in both exercise trials), and thus the relatively low activation requirement of this 
muscle during the exercise bouts may have also limited our ability to detect changes in 
the lipid pools of our muscle biopsy samples.  As such, given that we did not find 
significant changes in muscle triacylglycerol, diacylglycerol, or ceramide concentration 
after exercise, we must acknowledge the possibility that changes in fatty acid partitioning 
among the main lipid compartments in skeletal muscle may not be critical for the insulin 
sensitizing effect of exercise in obesity. 
 
In summary, although exercise is a key component in the treatment of obesity-related 
metabolic complications, including insulin resistance (16), it is astonishing that the 
“dose” of exercise required to improve insulin sensitivity in obese individuals at risk for 
the development of type 2 diabetes is not more clearly defined.  Due to the transient 
nature of the exercise-induced improvement in insulin sensitivity, we believe it is very 
important to develop exercise prescriptions aimed at maximizing the beneficial effects of 
each session of exercise.  Here we have demonstrated that expending only a modest 
amount of energy (350kcals) during a single session of exercise at a rather mild intensity 
(50% VO2peak) was sufficient to significantly improve insulin sensitivity at least into the 
next day in obese adults.  In addition to the effects of lowered muscle glycogen content 
on insulin sensitivity, evidence from this study also indicates that the insulin sensitizing 
effect of exercise in obesity may be mediated in part by attenuated systemic fatty acid 
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mobilization and uptake, though the underlying mechanism(s) for these effects are not 
known.  Finally, the findings from this study carry encouraging clinical implications 
given that the exercise performed in this investigation represents a substantial reduction 
in both the energy expenditure and intensity of exercise previously reported to 
significantly enhance insulin sensitivity in obese adults. 
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Table 4-1. Participant characteristics 
Age (y) 28 ± 2 
Body mass index (kg/m2) 37 ± 1 
Body mass (kg)             102 ± 3 
Body fat (%) 48 ± 2 
Fat mass (kg) 50 ± 3 
Fat free mass (kg) 53 ± 2 
VO2peak (ml/kg/min) 20 ± 1 






Table 4-2. Intensity, duration, and energy expended during the exercise sessions 
 EX50 EX65 P-value 
Intensity (% VO2peak) 51 ± 0 66 ± 0 < 0.001 
Duration (min) 70 ± 3 54 ± 2 < 0.001 
Energy Expended (kcal)           356 ± 3           355 ± 2    0.511 




Table 4-3. Fasting plasma insulin and substrate concentrations the day after exercise 
 CON EX50 EX65 P-value 
Insulin (μU/ml)       27.5 ± 4.4       28.0 ± 4.1       26.7 ± 3.7 0.79 
Glucose (mmol/L) 5.0 ± 0.1 5.2 ± 0.2 5.0 ± 0.1 0.26 
Fatty acid (mmol/L) 0.48 ± 0.05 0.40 ± 0.04 0.45 ± 0.02 0.09 
Triacylglycerol (mmol/L) 1.29 ± 0.18 1.40 ± 0.24 1.25 ± 0.19 0.24 




Table 4-4. Skeletal muscle immunoblot analysis in skeletal muscle samples collected the 
day after exercise  
 CON EX50 EX65 P-value 
GPAT1 4.4 ± 0.8 4.2 ± 0.8 4.0 ± 0.7 0.32 
DGAT1 2.1 ± 0.4 1.9 ± 0.3 2.0 ± 0.3 0.86 
DGAT2 3.5 ± 0.9 3.7 ± 0.9 4.4 ± 1.4 0.22 
Values are mean ± SEM, expressed in arbitrary units.  P-values are main effects from one-way, 





Figure 4-1. Timeline of experimental events.  Subjects participated in 3 separate two-day trials.  On two occasions subjects expended 
350kcals during an exercise session in the afternoon of the first day.  These two exercise trials were identical except for the intensity 
of exercise performed (50% VO2peak [EX50] and 65% VO2peak [EX65]).  Subjects also completed a control trial [CON] in which 
they remained sedentary.  RMR, resting metabolic rate; MTT, meal tolerance test; 13C-FA Inf, [1-13C]-palmitate isotope infusion; 








Figure 4-2. Plasma concentrations of: A. glucose and B. insulin measured during the 
meal tolerance test conducted 1h after exercise, or remaining sedentary.  Inset figures are 
calculated mean area under the plasma concentration curve for each trial.  For plasma 
glucose concentration (A), the two-way (treatment x time), repeated measures ANOVA 
P=0.17, and the main effect area under the curve one-way, repeated measures ANOVA 
P=0.09.  For plasma insulin concentration (B), the two-way (treatment x time), repeated 
measures ANOVA P=0.15, and the main effect area under the curve one-way, repeated 






Figure 4-3.  Insulin sensitivity measured via hyperinsulinemic-euglycemic clamp the day 
after exercise.   Data are expressed as clamped whole-body glucose disposal (Rd, 
(µmol/min)) per steady-state plasma insulin concentration (SSI, [µU/ml]).  *P<0.05 









Figure 4-4. A. Basal glucose rate of appearance in plasma (Ra) measured the day after 
exercise, *P<0.05 vs. CON.  B. Basal fatty acid rate of disappearance from plasma (Rd) 




A.           B.          C. 
 
Figure 4-5. Lipid content measured in skeletal muscle collected the day after exercise.  A. Skeletal muscle triacylglycerol (TAG) 




A.           B.          C. 
 
D.           E. 
Figure 4-6. Skeletal muscle insulin 
signaling, pro-inflammatory markers, and 
NAMPT measured in skeletal muscle 
collected the day after exercise.  The inset 
figure in each panel is representative blots 
for two subjects.  Both 54 and 46 kD bands 
presented in (D) for each subject are from 
the same blot.  The one-way, repeated 
measures ANOVA for (A) pIRS1Ser312 main 
effect P=0.72, (B) pPKCβThr641 main effect 
P=0.73, (C) IκBβ main effect P=0.26, (D) 
pJNK/JNK main effect P=0.08, (E) 







Figure 4-7.  Insulin sensitivity measured the day after exercise during EX65 vs. EX50.   
Data are expressed as clamped whole-body glucose disposal (Rd, (µmol/min)) per steady-
state plasma insulin concentration (SSI, [µU/ml]).  Females (n=8) are represented by 
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Physiologic mixtures of fatty acids do not impair insulin signaling in cultured 




In vitro experiments examining the effect of fatty acids on skeletal muscle insulin action 
are often limited to incubations using only 1 or 2 different fatty acid species, which 
obviously do not resemble a typical human plasma fatty acid profile.  The purpose of this 
study was to compare graded concentrations of 3 different lipid mixtures: 1) a 
physiologic fatty acid mixture (NORM; 30% oleate, 25% palmitate, 25% linoleate, 15% 
stearate, 5% palmitoleate), 2) a physiologic mixture high in saturated fatty acids (HSFA; 
20% oleate, 35% palmitate, 15% linoleate, 25% stearate, 5% palmitoleate), and 3) 100% 
palmitate (PALM) on in vitro insulin-stimulated phosphorylation of Akt (pAktThr308), as a 
marker of insulin signaling, as well as intracellular lipid accumulation in cultured muscle 
cells.  C2C12 myoblasts differentiated to myotubes were incubated for 12h in serum-free 
DMEM, 2% BSA, and either 0mM (control), 0.1, 0.2, 0.4, or 0.8mM fatty acid.  Insulin 
(100nM) was added for 15min before harvesting.  pAktThr308 was determined by 
immunoblot analysis, while diacylglycerol (DAG) and triacylglycerol (TAG) 
concentrations were measured in muscle lipid extracts using GCMS.  As expected, 
PALM significantly attenuated insulin-stimulated pAktThr308 compared with 0mM, and 
this was evident even at the lowest PALM concentration (0.1mM; P=0.001).  PALM 
treatment also markedly increased intracellular DAG content at 0.4 and 0.8mM (2.5- and 
5.4-fold compared with 0mM, respectively; both P<0.05).  In contrast, NORM resulted in 
only minimal impairment in insulin-stimulated pAktThr308 that was not evident at all 
NORM concentrations (including 0.8mM), and there was no impairment found with 
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HSFA.  Importantly, there was no increase in DAG concentration with NORM or HSFA; 
however, we found a dose-dependent increase in TAG accumulation with these 
physiologic fatty acid mixtures.  Our findings indicate the robust impairment in insulin 
signaling and increase in muscle DAG accumulation found with palmitate exposure was 
not evident with physiologic mixtures of fatty acids, even when the mixture contained a 





Obesity is characterized by excessive adiposity, and a resultant overabundance of fatty 
acids in the systemic circulation (24, 27, 40).  In turn, this elevation in systemic fatty acid 
availability has been identified as an important factor underlying several of the health 
complications common in obesity, including insulin resistance and type 2 diabetes (3, 5-
6, 46, 49-50, 56).  Excessive fatty acid uptake into insulin responsive tissues, like liver 
and skeletal muscle, has been linked with impaired insulin action in these tissues (5-6, 17, 
32, 40, 50).  Within skeletal muscle, although several studies have reported strong 
correlations between the severity of insulin resistance and the accumulation of 
intramyocellular triacylglycerol (TAG) (21, 30, 41, 43), it is now reasonably well-
accepted that increased accumulation of these neutral lipids within the myocyte is a 
relatively benign reservoir for fatty acid storage.  Alternatively, more highly reactive fatty 
acid metabolites, such as diacylglycerols (DAGs) and ceramides, may be more important 
for lipid-related impairment in insulin signaling within the muscle cell (1, 11-12, 23, 25, 
31, 39, 50, 55).  Previous work from our lab (STUDY 1) and (48, 50), and others (31, 34, 
44), suggests that when fatty acid availability and uptake into muscle is high (as in 
obesity), “partitioning” of the excess fatty acid toward TAG synthesis and storage may 
actually be favorable by limiting substrate available for the formation and accumulation 
of these more bioactive lipid intermediates within the muscle.  Nonetheless, the exact 
mechanisms underlying the effect of increased fatty acid availability on alterations in 
skeletal muscle lipid metabolism and the development of insulin resistance are still 
unclear. 
 
In addition to the effects of a general overabundance of systemic fatty acids on metabolic 
health, the health impact of the type of fatty acids (i.e., saturated vs. unsaturated) has 
garnered even more attention.  Diets high in saturated fatty acids have been linked with 
the accelerated development of several cardiometabolic abnormalities (for review see 
(10)).  Furthermore, studies performed in vitro have clearly established that saturated 
fatty acids (e.g., palmitate) induce a marked impairment in insulin action in cultured 
muscle cells (11-12, 39, 51-52).  But this is complicated by more recent findings by 
several investigators reporting that the addition of oleate (or other unsaturated fatty acids) 
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to palmitate incubations attenuates or even completely prevents the deleterious effect of 
palmitate on insulin signaling or insulin action in cultured muscle cells (13, 18, 47, 52).  
Clearly, incubating muscle cells with only one or two different fatty acids (and often in 
non-physiologic concentrations or proportions) does not provide an accurate reflection of 
the elevated fatty acid availability common in obesity.  Additionally the mechanisms 
underlying the putative negative effects of saturated fatty acid on insulin action and the 
possible salutary effects of unsaturated fatty acids are poorly understood.  Moreover, 
whether the saturation state of the fatty acid impacts the accumulation of different muscle 
lipids is not known.  To address these issues, the primary aim of this study was to 
determine the effect of increasing availability of physiologic mixtures of the five most 
abundant fatty acids in human plasma on insulin signaling and lipid accumulation in 
cultured myotubes.  We compared a fatty acid mixture designed to resemble the 
proportion of fatty acids found in plasma from a healthy human (60% unsaturated vs. 
40% saturated), with a mixture containing the same fatty acids but with the proportions 
modified to resemble (or exceed) a diet very high in saturated fatty acids (40% 
unsaturated vs. 60% saturated).  The effects of these fatty acid mixtures on insulin 
signaling and lipid accumulation were compared with the effects of muscle cells 




Mouse C2C12 myoblasts (American Type Culture Collection, Manassas, VA) were 
grown in high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10% (v/v) fetal bovine serum and 1% (v/v) antibiotic-antimycotic solution in 100mM 
tissue culture treated plates.  All cells were passed 3-5 times, and ultimately plated in 6-
well, 35mM/well tissue culture treated plates.  Upon reaching ~70% confluence, 
myoblasts were switched to high glucose (~25mM) DMEM supplemented with 2% (v/v) 
horse serum and 1% (v/v) antibiotic-antimycotic solution to induce differentiation.  This 
media was replaced at 48 h.  At 96 h (4 d), differentiated myotubes were used in the 
experiments described below. All cell culture media and media supplements were 
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purchased from Gibco-Invitrogen (Grand Island, NY). All other chemicals used in cell 
culture were purchased from Sigma-Aldrich (St. Louis, MO). 
  
Experimental design  
Experimental protocol 
Sets of differentiated myotubes were incubated for 12 hours in media containing low 
glucose (~5mM), serum-free DMEM supplemented with 1% (v/v) antibiotic-antimycotic 
solution, and 2% (w/v) fatty acid-free bovine serum albumin (BSA) supplemented with 
one of three different fatty acid mixtures: 1) a normal physiologic mixture of fatty acids 
generally reflecting their proportion in plasma of a healthy human (NORM; 30% oleate 
[C18:1], 25% linoleate [C18:2], 25% palmitate [C16:0], 15% stearate [C18:0], and 5% 
palmitoleate [C16:1]), 2) a physiologic mixture of fatty acids designed to resemble a diet 
very high in saturated fatty acids (HSFA; 20% oleate, 15% linoleate, 35% palmitate, 25% 
stearate, and 5% palmitoleate), or 3) 100% palmitate (PALM).  The NORM and HSFA 
fatty acid mixtures were formulated by Nu-Chek Prep Inc (Elysian, MN).  We performed 
incubations at 4 different concentrations of each of the 3 fatty acid mixtures (0.1mM, 
0.2mM, 0.4mM, or 0.8mM), and we also included a no fatty acid control (0.0mM).  
Therefore, we compared 13 different fatty acid conditions (i.e., 3 fatty acid mixtures x 4 
concentrations = 12 + control = 13).  Importantly, because our concentrated fatty acid 
supplements were prepared in ethanol, all final incubation media (including 0.0mM) 
contained 0.5% (v/v) ethanol.  After the 12 hr incubation in the different fatty acid 
treatments, myotubes were treated with or without insulin (100nM) for 15min, and then 
harvested for later analysis (see details in “Cell harvest” section, below).  At least n=3 
experiments were performed for all conditions.  
 
Experimental outcome variables 
To assess insulin action in response to the various treatment conditions, both basal (i.e., 
no insulin treatment) and insulin-stimulated phosphorylation of key insulin signaling 
proteins was determined via western blot analysis.  Target proteins included 
phosphorylated (p) AktThr308, glycogen synthase kinase-3 (GSK3α/βSer21/9), and Akt 
substrate of 160kD (AS160Thr642).  Additionally, harvested myotubes were tested for 
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myocellular diacylglycerol (DAG) and triacylglycerol (TAG) accumulation (see 
“Cellular triacylglycerol and diacylglycerol concentrations” below).  Protein abundance 
of putative regulators of muscle cell lipid accumulation, including of key lipogenic, 
lipolytic, and lipid transport proteins was examined via western blot analysis.  Lipogenic 
protein targets included the enzymes glycerol-3-phosphate acyltransferase (GPAT1) and 
diacylglycerol acyltransferase (DGAT1), which catalyze the first and final steps of 
committed TAG synthesis, respectively.  Adipose triacylglycerol lipase (ATGL), its 
activating co-factor comparative gene identification 58 (CGI-58), hormone sensitive 
lipase (HSL), and activation phosphorylation of HSL (pHSLSer563) comprised the lipolytic 
protein targets, while abundance of the fatty acid transporter fatty acid translocase 
(FAT/CD36) was measured as a marker of myotube fatty acid transport capacity.  
Finally, markers of proinflammatory/stress activation, including phosphorylation of c-jun 
N-terminal kinase (pJNKThr183Tyr185), protein kinase C (pPKCβThr641
 
), and protein 
abundance of the NF-κB inhibitor IκBβ, were also determined via western blot analysis.  
Importantly, all measures of lipid accumulation, lipid metabolism regulatory proteins, 
and markers of inflammatory pathway activation were made using lysates from basal 
(i.e., non insulin treated) myotubes. 
Analytical procedures 
Cell harvest 
Cells were rinsed twice with ice-cold Dulbecco’s phosphate buffered saline (DPBS), 
treated with lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 1mM Na2EDTA pH 8.0, 
1mM EGTA pH 8.0, 1% (v/v) Triton X-100, 2.5mM NaPP, 1mM β-glycerophosphate, 
1mM Na3VO4, and 1x SigmaFAST protease inhibitor cocktail), and scraped on ice into 
microfuge tubes.  Lysates were centrifuged at 20,000 g for 10 min at 4oC.  Supernatants 
were collected and tested for protein concentration (Pierce BCA protein assay, Thermo 
Scientific, Rockford, IL).  For cell lipid content assays (described below), DPBS was 
used as a harvest solution and lysates were not centrifuged prior to use in cell lipid 
content assays. 





20-30 µg of protein were separated by SDS-PAGE and transferred to nitrocellulose 
membranes.  Various proteins were targeted within whole cell lysates with primary 
antibodies against: Akt (9272; Cell Signaling Technology, Danvers, MA), pAktThr308 
(9275; Cell Signaling Technology), GSK3β (9315; Cell Signaling Technology), 
pGSK3α/βSer21/9 (9331; Cell Signaling Technology), AS160 (ABS54; EMD Millipore, 
Billerica, MA), pAS160Thr642 (3028 P1; Symansis, Auckland, New Zealand), GPAT1 
(4613; ProSci Incorporated, Poway, CA), DGAT1 (NB110-41487; Novus Biologicals, 
Littleton, CO), ATGL (2138; Cell Signaling Technology), CGI-58 (NB110-41576; 
Novus Biologicals), HSL (4107; Cell Signaling Technology), pHSLSer563 (4139; Cell 
Signaling Technology), FAT/CD36 (sc-9154; Santa Cruz Biotechnology, Santa Cruz, 
CA), JNK (9251; Cell Signaling Technology), pJNKThr183Tyr185 (4671; Cell Signaling 
Technology), pPKCβThr641 (07-873; EMD Millipore), and IκBβ (9248; Cell Signaling 
Technology).  Membranes were incubated with appropriate secondary antibodies and 
developed using enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ).  
Bands were imaged and then quantified via densitometry (AlphaEaseFC, Alpha Innotech 
Corp., Santa Clara, CA).  Data are presented in arbitrary units relative to values obtained 
for 0.0mM (control) treated myotubes that were normalized to one.  
 
Cellular triacylglycerol and diacylglycerol concentrations 
Cells were harvested in ice-cold DPBS, and lipids were extracted overnight at 4°C in a 
single-phase mixture of chloroform-methanol-aqueous homogenate (1:2:0.8, v/v/v) (4).  
Internal lipid markers for TAG, DAG, monoacylglycerol, non-esterified fatty acid 
(NEFA), phospholipid (PL), and cholesterol ester having fatty acid moieties of odd 
carbon number were added at the start of extraction, for subsequent purity and recovery 
determinations (Nu-Chek Prep Inc.; Avanti Polar Lipids Inc., Alabaster, AL). TAG, DAG 
and PL markers were each homogenous in fatty acid content (e.g., [C23:0]3-TAG).  
Extraction was ended by addition of sufficient chloroform and saline to form two phases 
(2:2:1.8).  After vortexing and brief centrifugation, the lower chloroform phase 
containing lipids was transferred to a clean tube and dried under vacuum.  The residue 
was reconstituted in 100 µl chloroform and applied to a hexane-equilibrated, 
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aminopropyl solid phase extraction column.  The small chloroform volume did not 
significantly alter the hexane equilibrium, permitting virtually complete adsorption of 
glycerolipid and NEFA.  Individual lipid species were eluted using previously described 
solvent mixtures (7).  Column fractions were dried, and those containing either purified 
TAG or DAG were reconstituted in 100 µl toluene.  Fatty acid methyl esters (FAMEs) 
were then generated via alkaline methanolysis, a transesterification process (7), by 
addition of 1.0 ml 0.2N NaOH in methanol having ultra-low H2O content, in order to 
exclude hydrolysis.  After 1h incubation at room temperature, the reaction was 
neutralized using 0.9 ml 1.0 M Na-acetate (pH 4.75).  Chloroform (1.0 ml) was added for 
two-phase formation, which was unaffected by the small volume of toluene present.  The 
lower chloroform phase containing FAMEs from TAG or DAG was transferred, dried 
and reconstituted in heptane.  Individual FAMEs were purified by gas chromatography 
with capillary column (GC/MS; Agilent 5973Networks, Mass Selective Detector; 
 
Agilent 
Technologies, Palo Alto, CA).  FAMEs were detected by electron-impact mass 
spectrometry with selective ion monitoring, and quantified using FAME standards. 
Statistical analysis   
A two-way (dose x treatment type) analysis of variance (ANOVA) was used to test for 
significant differences in factor means for all outcome variables. Tukey’s post-hoc pair-
wise analysis was used to examine significant F values detected during ANOVA 




As anticipated, incubating the myotubes in PALM suppressed insulin-stimulated 
pAktThr308, and this PALM-induced impairment in pAktThr308 was largely dose-dependent 
(Figure 5-1a).  PALM suppressed pAktThr308 even at our lowest dose (0.1mM; P=0.001), 
and at 0.8mM PALM, insulin-stimulated pAktThr308 was only about one-third of that 
found when no fatty acids were added to the incubation medium (0.0mM; P<0.001).  In 
contrast, although incubating myotubes in a mixture of fatty acids intended to resemble a 
“normal” plasma fatty acid profile (NORM) did significantly lower insulin-stimulated 
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pAktThr308 (Figure 5-1a), this suppression was relatively modest and was not evident at all 
treatment doses, including the highest treatment dose (0.8mM).  Surprisingly, overnight 
exposure to our fatty acid mixture containing a high proportion of saturated fatty acids 
(HSFA) did not significantly attenuate insulin-stimulated pAktThr308 at any treatment dose 
(Figure 5-1a), and there were no differences between NORM and HSFA at any dose. 
 
Despite marked attenuation in insulin-stimulated pAktThr308 in PALM-treated myotubes, 
we did not find a robust suppression in insulin-stimulated phosphorylation of targets 
downstream of Akt.  Phosphorylation of GSK (pGSK3α/βSer21/9) did tend to decline with 
increasing doses of PALM (Figure 5-1b), and we did find a significant main effect for 
pGSK3α/βSer21/9 to be lower in PALM compared with NORM and HSFA (both P<0.05).  
However, there was no apparent effect on pAS160Thr642 after exposure to any of the 
various treatments, at any treatment dose (Figure 5-1c).  Importantly, the insulin 
stimulated increase in pGSK3α/βSer21/9 and pAS160Thr642 were rather modest compared 
with the effect of insulin on pAktThr308 (Figure 5-2a – lanes 1 and 2).  In addition it is 
important to note that total Akt, GSK3β, and AS160 protein abundance and basal (i.e., 
non-insulin stimulated) phosphorylation were not altered by exposure to any of the 
various treatments, at any treatment dose (representative blots are shown in Figure 5-2b). 
 
Lipid accumulation 
In parallel with our pAktThr308 data, PALM incubation increased cellular DAG content in 
a dose-dependent manner (Figure 5-3a).  The increase in DAG content was significantly 
elevated at the 0.4mM (P=0.02) and 0.8mM (P<0.001) treatment doses compared with 
0.0mM.  Conversely, neither NORM nor HSFA increased DAG content at any treatment 
dose (Figure 5-3a), and cellular DAG content was significantly greater in PALM 
compared with both NORM and HSFA at 0.8mM (P<0.001).  Interestingly, the pattern of 
change in cellular TAG content in response to the different treatments was nearly 
opposite to that of DAG.  Incubating the myotubes in NORM and HSFA increased 
cellular TAG content markedly, and in a dose-dependent manner.  Even the low doses of 
these lipid mixes induced a significant increase in TAG (Figure 5-3b).  PALM treatment 
did augment TAG content, but this effect was only statistically significant at the higher 
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doses (0.4 and 0.8mM) and TAG accumulation at these higher doses of PALM was still 
only about half as great as that measured with NORM and HSFA treatments (both 
P<0.01; Figure 3b).  The constituent fatty acids that comprised both the cellular DAG and 
TAG pools are provided in Tables 5-1 and 5-2, respectively.  In general, the fatty acid 
composition of both DAG and TAG tended to resemble the fatty acid(s) provided in the 
incubation media, particularly at the higher treatment doses when lipid accumulation was 
greatest.  However, it is noteworthy that oleate (C18:1) tended to be slightly 
overrepresented whereas stearate (C18:0) tended to be slightly underrepresented (relative 
to the respective contributions to the incubation mixtures), particularly in the cellular 
TAG pools.   
 
Lipid metabolism proteins 
Despite marked accumulation of TAG with increasing dose of fatty acids, we found no 
change in protein abundance of the TAG synthesis enzyme GPAT1 (Figure 5-4a).  
Similarly, DGAT1 abundance was not elevated above 0.0mM in any of our different fatty 
acid treatments, but we did find DGAT1 protein abundance to be consistently greater in 
the HSFA treated myotubes compared with both NORM and PALM (main effect for 
treatment type, both P<0.01).  In contrast to the limited changes in TAG synthesis 
enzymes, there was a robust, dose-dependent increase in protein abundance of the TAG 
lipase ATGL (Figure 5-5a).  The increase in ATGL protein abundance was similar for all 
of our fatty acid treatments and achieved statistical significance at 0.4mM (P=0.003) and 
0.8mM (P<0.001) compared with 0.0mM (Figure 5-5a).  This effect of increasing fatty 
acid concentration on protein abundance was not found for the ATGL co-activator CGI-
58, or HSL (Figure 5-5b and 5-5c, respectively).  Interestingly, similar to DGAT1, CGI-
58 protein abundance was slightly but consistently elevated in the HSFA treated 
myotubes compared with both NORM and PALM treated myotubes (main effect for 
treatment type, both P<0.02).   
 
Proinflammatory stress markers 
Phosphorylation of JNK at threonine 183 and tyrosine 185 residues was consistently 
elevated in PALM treated myotubes compared with both NORM and HSFA treated 
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myotubes (Figure 5-6a; main effect for treatment type, both P<0.01).   Total JNK protein 
abundance was not affected by any of our fatty acid treatments (data not shown).  In 
contrast to the phosphorylation of JNK, PKCβ phosphorylation at the threonine 641 
residue was unaffected by increasing concentrations of any of our fatty acid treatments 
(Figure 5-6b).  IκBβ protein abundance was measured as a marker of NFκB pathway 
activation, and similar to pPKCβThr641, IκBβ was also not significantly altered by any of 
our lipid treatments (Figure 5-6c). 
 
Discussion 
The effects of palmitate exposure on in vitro muscle cell metabolism have been examined 
for decades (16), and the negative effect of palmitate on insulin signaling in cultured 
myotubes has been very well established (12, 15, 19, 39, 51-53, 58).  More recently, it 
has been demonstrated that the addition of an unsaturated fatty acid (such as oleate) to 
palmitate in the incubation media can attenuate, and even completely prevent the 
deleterious effect(s) of palmitate on insulin signaling and/or insulin action in cultured 
muscle cells (13, 18, 47, 52).  However, exposing muscle cells to media containing only 
two different fatty acids (and often in non-physiologic concentrations or proportions) 
does not provide an accurate reflection of the elevated fatty acid availability common in 
obesity.  Our findings expand on the previous studies in this area by demonstrating that 
when cultured myotubes were exposed to physiologic proportions of the five most 
abundant fatty acids found in humans, insulin-stimulated phosphorylation of Akt was 
only minimally impaired, even at concentrations that represent relatively high 
physiologic levels (0.8mM).  Moreover, our novel findings indicate that even a fatty acid 
mixture containing a relatively high proportion of saturated fatty acids (i.e., resembling or 
even exceeding the proportion of saturated fatty acids found in a very high saturated fat 
diet) also failed to induce substantial impairment in insulin-stimulated phosphorylation of 
Akt.  In conjunction with these findings, we also found that incubation in both of these 
fatty acid mixtures augmented intramyocellular TAG concentration without an increase 
in DAG accumulation.  Not only does this confirm that the fatty acids in our physiologic 
mixtures were indeed entering the myotubes in our experiments, but also their 
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preferential storage as neutral lipids may help explain why exposure to even high 
concentrations of these mixtures did little to suppress insulin signaling.   
 
Although several studies have reported strong correlations between intramyocellular 
TAG concentration and the severity of insulin resistance (21, 30, 41, 43), it is now 
reasonably well-accepted that intramyocellular TAGs represent a relatively benign 
reservoir for fatty acid, and more highly reactive fatty acid metabolites, such as DAGs 
and ceramides, may impair insulin signaling (1, 11-12, 23, 25, 31, 39, 50, 55).  Previous 
work from our lab STUDY 1 and (48, 50), and others (31, 34, 44), suggests that when 
fatty acid availability and uptake into muscle is high (as in obesity), “partitioning” of the 
excess fatty acid toward TAG synthesis and storage may be favorable by limiting 
substrate available for the formation and accumulation of these more bioactive lipid 
intermediates within the muscle.  In line with this hypothesis, here we found that the 
highest doses of our NORM and HSFA treatments (0.8mM) resulted in a ~10-fold 
increase in TAG accumulation, with no increase in DAG concentration, and insulin-
stimulated Akt phosphorylation was only minimally suppressed.  In contrast, PALM 
treated myotubes were characterized by attenuated TAG accumulation, robust DAG 
accumulation, and insulin-stimulated Akt phosphorylation was severely impaired.  Thus, 
as compared with an equivalent dose of palmitate, there clearly was a preferential 
"partitioning" of the fatty acids in NORM and HSFA treatments to be esterified and 
stored as TAG.  It has been previously suggested that the TAG synthesis pathway 
(perhaps most importantly DGAT) may have a higher affinity for unsaturated fatty acids 
compared with saturated fatty acids (12, 39), which may contribute to elevated TAG 
accumulation when the availability of unsaturated fatty acids is high.  However, a high 
affinity for unsaturated fatty acids may not explain the high TAG accumulation with the 
lipid mixtures in our study because we found a similar increase in TAG accumulation 
with our NORM and our HSFA treatments, despite the marked difference in the 
proportion of unsaturated fatty acids in these mixtures (i.e., 60% vs. 40%, respectively).  
Additionally, if TAG synthesizing enzymes had a greater affinity for the unsaturated fatty 
acids in our lipid mix, we would expect to find a much higher proportion of unsaturated 
fatty acids within the TAG fraction of our muscle cells, but instead the fatty acid profiles 
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within our TAG fraction generally resembled the fatty acid profile in the incubation 
media.  It is not clear why lipid accumulation in our muscle cells was nearly identical 
between NORM and HSFA, but akin to our observations for insulin signaling, it appears 
that as long as a generally physiologic mixture of several fatty acids was provided, a 
relatively high proportion of saturated fatty acids did not abnormally affect fatty acid 
“partitioning” or lipid accumulation.  
 
Many factors may contribute to the differential accumulation of fatty acids within 
separate lipid pools (e.g., TAG and DAG), with the most likely targets being the 
regulation of lipid synthesis, lipolysis, as well as the transport of fatty acids into the 
myocyte.  We (STUDY 1) and (50), and others (35, 44), have previously suggested that 
altered abundance and/or activity of key lipogenic enzymes may help to facilitate the 
partitioning of excess fatty acid in muscle cells toward TAG synthesis (and away from 
DAG and ceramide accumulation), which may in turn improve muscle cell insulin action.  
However, in general our findings do not support this notion under the present conditions.  
Our observation that intramyocellular TAG concentration increased up to ~10-fold 
without a change in protein abundance of the key TAG synthesizing enzymes, GPAT and 
DGAT, suggests that the basal abundance of these enzymes was sufficient to catalyze this 
robust increase in TAG synthesis, and is not likely limiting fatty acid accumulation as 
TAG in our experiments.  It is certainly possible that post-translational modifications of 
these proteins may have altered the enzymatic activity of GPAT1 and/or DGAT1 (not 
measured in this study), but such modifications have not been well investigated.   
 
Although alterations in the TAG synthesis pathway could certainly contribute to the 
pattern of intramyocellular lipid accumulation, regulation of lipid hydrolysis may also be 
very important.  It has been hypothesized that the balance between TAG lipase (ATGL) 
and DAG lipase (HSL) activity could be a key determinant of the accumulation of 
intramyocellular TAG and DAG (2).  Here we found a dose-dependent increase in the 
abundance of the TAG lipase ATGL for all three of our fatty acid treatments, while there 
was no change in HSL protein content, or activating phosphorylation at Ser563 (data not 
shown), with any concentration of any of our treatments.  This apparent lipolytic 
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regulatory enzyme imbalance did not correspond with our DAG accumulation data, 
which was only elevated in response to PALM treatment.  We acknowledge that ATGL 
protein abundance does not necessarily reflect lipase activity, and note that the abundance 
of the ATGL co-activator, CGI-58, did not increase in parallel with ATGL, which may 
have helped to mitigate lipolytic activity even when ATGL abundance was very high.  
Pertaining to the potential mechanism underlying the dose-dependent increase in ATGL 
that we observed, ATGL expression is known to be mediated by peroxisome proliferator-
activated receptor-γ (PPARγ) (29, 36).  Because fatty acids are known ligands/activators 
of PPARs (28) it is likely that the increased availability of fatty acids in our incremental 
fatty acid exposures augmented ATGL abundance via a PPARγ-dependent mechanism.  
Importantly, because the upregulation of ATGL abundance was essentially the same for 
all three of our fatty acid treatments, it appears that the increase in ATGL abundance was 
responding largely to the quantity of fatty acid(s) rather than the species of fatty acid(s).   
 
We have reported in STUDY 1 and elsewhere (33) that fatty acid transport capacity may 
be an important determinant for the accumulation of muscle lipids.  However, here we 
found no change in protein abundance of the predominant skeletal muscle fatty acid 
transporter FAT/CD36 with any treatment.  It is possible that altered localization of 
FAT/CD36, as well as changes in other fatty acid transporters, may have mediated altered 
fatty acid uptake in the myotubes given that FAT/CD36 has been shown to translocate 
from intracellular pools to the cell surface membrane in response to several different 
stimuli (8, 26, 38).  Nonetheless, our findings indicate that the basal abundance of 
FAT/CD36 in these myotubes was likely sufficient to facilitate enough fatty acid 
transport to induce a ~10-fold increase in TAG content during NORM and HSFA 
treatments. 
 
Excess DAG is hypothesized to attenuate insulin action via induction of proinflammatory 
stress signaling pathways that have been shown to negatively regulate insulin signaling 
proteins and GLUT4 trafficking (14, 25, 52, 57).  In agreement with this hypothesis, 
NORM and HSFA treated cells did not accumulate DAG, we found no change in the 
phosphorylation of the proinflammatory stress kinase JNK, and subsequently insulin 
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stimulated Akt phosphorylation was only marginally attenuated compared with when no 
fatty acids were added to the incubation medium.  In contrast, in our PALM treated cells 
the increase in DAG concentration was accompanied by an increase in pJNK, and 
impaired insulin stimulated Akt phosphorylation.  However, the effect of PALM 
treatment on JNK phosphorylation appeared to be independent of the dose of palmitate, 
and thus did not parallel the dose-dependent effect we found with cellular DAG 
accumulation.  While it is possible that the resolution of our assessment of pJNK was not 
sensitive enough to detect a dose-dependent response, it is more likely that additional 
factors other than JNK activation during PALM treatment also mediate the impairment in 
insulin signaling.  For example, palmitate has previously been reported to have 
pronounced cytotoxic (i.e., cell death) effects in muscle cells in vitro when provided in 
high concentrations (e.g., 0.75mM) (53), and this may also contribute to the palmitate-
related impairment in insulin-stimulated Akt phosphorylation.  Because the novel 
component of the present study was to examine the effects of physiologic fatty acid 
mixtures on insulin signaling and lipid metabolism, and most importantly, myotubes 
exposed to these treatments did not show any sign of pronounced insulin signaling 
impairment, measures of cell viability were not performed in these experiments.  Equally 
important is that skeletal muscles from high fat-fed and ob/ob mice (i.e., murine models 
of obesity-related excessive fatty acid availability) do not exhibit increased pro-apoptotic 
(i.e., cell death) activation (54), thus indicating that lipid-related cytotoxicity is not likely 
relevant for in vivo skeletal muscle cell physiology and lipid-related insulin resistance.   
 
We must also acknowledge that deleterious effects of palmitate and/or other saturated 
fatty acids on insulin action and/or proinflammatory stress activation could certainly be 
due to factors in addition to alterations in lipid accumulation and fatty acid partitioning, 
per se.  For example, increased saturated fatty acid availability has been found to alter 
cell membrane structure and function, and increased saturated fatty acid content in the 
muscle cell membrane phospholipid pool has been associated with impaired insulin 
action (9, 42).  This association may be mediated in part by impaired membrane fluidity, 
and a resulting attenuation in insulin receptor content and insulin binding at the cell 
membrane (20, 22).  Differential transport, trafficking, and perhaps oxidation of saturated 
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vs. unsaturated fatty acids may also have implications for cellular metabolism and insulin 
action; however, compelling evidence to suggest that the saturation state of the fatty acid 
influences these properties of cellular lipid metabolism is currently lacking.  It is 
important to reemphasize that despite a relatively large difference in the saturated fatty 
acid content in our NORM and HSFA lipid mixtures, we observed essentially no 
difference in our primary outcome measures.  This suggests that when muscle cells are 
exposed to the most abundant fatty acids found in human plasma in generally physiologic 
proportions and concentrations, the saturation state of the available fatty acids may not be 
an important factor for the regulation of lipid partitioning/accumulation or insulin 
signaling within the cell. 
 
Given that both GSK3α/β and AS160 are downstream signaling targets of the 
serine/threonine kinase Akt, we were surprised that the deleterious effect of PALM 
treatment on insulin-stimulated phosphorylation of Akt was not paralleled by impaired 
insulin-stimulated phosphorylation of GSK3α/β and AS160.  Upon review of our insulin 
signaling data, these observations are likely due to a limitation in our ability to detect 
changes in the phosphorylation of GSK3α/β and AS160 compared with Akt in our model, 
rather than due to a true disconnect in these well-established signaling cascades.  For 
example, in our muscle cells incubated without fatty acid (0.0 mM), insulin treatment 
resulted in a >10-fold increase in Akt phosphorylation compared with the basal condition 
(i.e., non insulin treated), whereas insulin-stimulated phosphorylation of GSK3α/β and 
AS160 was only ~2-fold and a mere 50% above the basal condition, respectively (see 
Figure 5-2 for representative blots).  This limited range for the change in phosphorylation 
for these downstream signaling proteins under conditions without fatty acid likely 
diminished our ability to detect a decrement in the phosphorylation of these proteins in 
the PALM treated myotubes.  We are currently conducting related follow-up studies in 
human primary skeletal muscle cell culture to combat this unfortunate limitation, and to 
determine whether our current findings can be extended to a human muscle cell model.  
 
Several unresolved questions remain pertaining to the effects of fatty acids on insulin 
signaling and insulin action.  We recognize that findings in cell culture may not fully 
116 
 
translate to humans in vivo, but from our work here and the work of others (13, 18, 47, 
52) it appears that as long as there are some unsaturated fatty acids present, the negative 
effects of saturated fatty acids on muscle insulin action are largely abolished.  So because 
more than half of the fatty acids in human plasma are unsaturated (37, 45), even in 
individuals who eat diets containing a high proportion of saturated fat (45), does a 
relatively high proportion of plasma saturated fatty acids really present a meaningful 
health risk in the context of muscle insulin resistance, as is commonly believed?  
Alternatively, while at relatively low concentrations unsaturated fatty acids may 
somehow abrogate the negative effects of saturated fatty acids (such as palmitate), but 
perhaps as the availability of fatty acids increase, the resultant high fatty acid flux into 
muscle impairs insulin action regardless of the saturation state.  This concept is supported 
by many clinical studies in humans that report marked suppression in insulin sensitivity 
in response to infusion of lipid emulsion solutions that are comprised almost entirely of 
unsaturated fatty acids (5-6, 49).  Importantly, we recently reported that even a rather 
modest infusion rate of a lipid emulsion solution containing ~90% unsaturated fatty acids 
can impair insulin sensitivity in humans (50), so the infusion rates and resultant fatty 
availability do not need to be supraphysiological in order to observe this phenomenon.  
Perhaps the balance between the fatty acid flux into muscle and the capacity to sequester 
the transported fatty acids into neutral lipids within the myocyte plays a key role.  Along 
these lines, despite the relatively high physiologic concentrations of the fatty acid 
mixtures used in our experiments, this did not appear sufficient to overwhelm the 
capacity of the myotubes to store these fatty acids as triacylglycerols.  As a result, even at 
the highest concentration of either of our fatty acid mixtures (0.8mM) we found no 
accumulation of more bioactive lipid intermediates (e.g., DAG), no signs of increased 
activation of pro-inflammatory pathways (e.g., JNK), and insulin signaling was not 
impaired.  In contrast to our findings, a recent study has demonstrated that higher doses 
of long-chain polyunsaturated fatty acids did indeed impair insulin action in cultured 
muscle cells (47).  It is very important to consider that the while in vitro experiments like 
ours incubate the muscle cells in elevated fatty acid concentrations for several hours, in 
human obesity muscles are chronically exposed to elevated fatty acid availability, and it 
appears that regardless of the proportion of saturated vs. unsaturated fatty acids in plasma 
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this chronic over-exposure may overwhelm the capacity for triacylglycerol synthesis, 
which may ultimately contribute to impaired insulin sensitivity. 
 
In summary, we found that physiologic mixtures containing the five most abundant 
plasma fatty acids did not substantially impair muscle cell insulin signaling in vitro when 
provided acutely (12h), and in doses that span the normal-to-high range of physiologic 
plasma fatty acid concentrations (0.1-0.8mM).  This was the case even when the saturated 
fatty acid content of the mixture was raised to levels that resemble or even exceed the 
proportion of saturated fatty acids found in a very high saturated fat diet.  Importantly, 
both of our fatty acid mixtures dose-dependently increased triacylglycerol accumulation 
in the muscle cells, and in turn diacylglycerol content did not increase.  Therefore, our 
findings support the working hypothesis that as long as the availability and flux of fatty 
acid into muscle does not exceed the capacity to esterify and store these fatty acids as 
triacylglycerols this may help limit the accumulation of more harmful lipid intermediates, 
such as diacylglycerol, and thereby “protect” against fatty acid-induced insulin resistance.  
Moreover, our findings indicate that as long as some unsaturated fatty acids were present, 
a high proportion of saturated fatty acids did not have an adverse effect on the regulation 
of lipid accumulation or insulin signaling.  
 
Acknowledgments 
We are very grateful to Christopher L. Mendias, Ph.D. for his outstanding technical 
assistance with cell culture methodology.  We also acknowledge Allison C. Everett for 
her general assistance with all aspects of this project, and Alexander Hinko, Ph.D., for 
developing and executing the muscle triacylglycerol and diacylglycerol methodology.  
This work was also supported by NIH Grant #R01 DK077966, awarded to J.F.H.  
118 
 
Table 5-1. Fatty acid composition of cellular diacylglycerol (% of the total 
diacylglycerol fatty acid pool) 
Treatment 
Type mM C16:0 C18:0 C16:1 C18:1 C18:2 
No fatty acid 
(Control) 0.0 24% 3% 17% 49% 4% 
PALM incubation media  100% 0% 0% 0% 0% 
PALM 0.1 42% 22% 9% 25% 1% 
PALM 0.2 50% 23% 8% 17% 0% 
PALM 0.4 54% 18% 9% 17% 1% 
PALM 0.8 76% 12% 5% 7% 0% 
NORM incubation media 25% 15% 5% 30% 25% 
NORM 0.1 22% 24% 4% 37% 11% 
NORM 0.2 21% 25% 6% 34% 13% 
NORM 0.4 26% 28% 3% 30% 13% 
NORM 0.8 24% 26% 3% 29% 17% 
HSFA incubation media 35% 25% 5% 20% 15% 
HSFA 0.1 20% 22% 13% 43% 2% 
HSFA 0.2 23% 18% 6% 49% 3% 
HSFA 0.4 24% 13% 9% 45% 9% 
HSFA 0.8 32% 14% 8% 36% 10% 
Values are means for n=3 expressed as a percentage of the total triacylglycerol fatty acid 
pool.  The composition of the different fatty acid treatments in the incubation media is 




Table 5-2. Fatty acid composition of cellular triacylglycerol (% of the total 
triacylglycerol fatty acid pool) 
Treatment 
Type mM C16:0 C18:0 C16:1 C18:1 C18:2 
No fatty acid 
(Control) 0.0 24% 3% 17% 49% 4% 
PALM incubation media  100% 0% 0% 0% 0% 
PALM 0.1 50% 1% 14% 31% 2% 
PALM 0.2 62% 2% 11% 22% 2% 
PALM 0.4 72% 1% 9% 16% 1% 
PALM 0.8 83% 2% 5% 8% 1% 
NORM incubation media 25% 15% 5% 30% 25% 
NORM 0.1 22% 4% 10% 51% 12% 
NORM 0.2 21% 5% 7% 49% 17% 
NORM 0.4 23% 7% 5% 43% 22% 
NORM 0.8 24% 8% 3% 39% 25% 
HSFA incubation media 35% 25% 5% 20% 15% 
HSFA 0.1 28% 6% 12% 46% 7% 
HSFA 0.2 31% 7% 9% 44% 8% 
HSFA 0.4 34% 10% 6% 40% 10% 
HSFA 0.8 35% 14% 4% 35% 12% 
Values are means for n=3 expressed as a percentage of the total triacylglycerol fatty acid 
pool.  The composition of the different fatty acid treatments in the incubation media is 








Figure 5-1. Insulin-stimulated phosphorylation of insulin signaling proteins.  In all figure panels, pAktThr308 (A), pGSK3α/βSer21/9 (B), 
and pAS160Thr642 (C), data are expressed relative to a no fatty acid (0.0mM) condition.  *P<0.05 vs. 0.0mM.  †P<0.05 vs. NORM and 
HSFA within treatment dose.  #P<0.05 for a main effect of PALM vs. NORM and HSFA.  Representative blots are inset above each 











Figure 5-2. Representative blots for basal phosphorylation of insulin signaling proteins 
(A) and total abundance of insulin signaling proteins (B).  In panel (A), insulin stimulated 
phosphorylation of each insulin signaling protein during no fatty acid (0.0mM) treatment 
is presented in the far left lane of each representative blot.  GSK, glycogen synthase 










Figure 5-3. Muscle cell lipid accumulation.  In both figure panels, DAG (A) and TAG 
(B), data are expressed relative to a no fatty acid (0.0mM) condition.  *P<0.05 vs. 
0.0mM.  †P<0.05 vs. NORM and HSFA within treatment dose.  ‡P<0.05 vs. HSFA 









Figure 5-4. Protein abundance of triacylglycerol synthesis enzymes GPAT1 (A) and 
DGAT1 (B).  In both figure panels data are expressed relative to a no fatty acid (0.0mM) 
condition.  #P<0.05 for a main effect of HSFA vs. PALM and NORM.  Representative 
blots are inset above each figure panel.  GPAT, glycerol-3-phosphate acyltransferase; 
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Figure 5-5. Protein abundance of lipolytic regulators ATGL (A), CGI-58 (B), and HSL (C).  In all figure panels data are expressed 
relative to a no fatty acid (0.0mM) condition.  In panel (A) #P<0.05 for a main effect of treatment dose vs. 0.0mM.  In panel (B) 
#P<0.05 for a main effect of HSFA vs. PALM and NORM.  Representative blots are inset above each figure panel.  ATGL, adipose 









Figure 5-6. Markers of proinflammatory stress activation.  In all figure panels, pJNKThr183/Tyr185 (A), pPKCβThr641 (B), and IκBβ (C), 
data are expressed relative to a no fatty acid (0.0mM) condition.  #P<0.05 for a main effect of PALM vs. NORM and HSFA.  
Representative blots are inset above each figure panel.  Both 54 and 46 kD bands presented in (A) for each fatty acid treatment type 
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It is very well established that both type 2 diabetic and pre-diabetic populations are 
characterized by insulin resistance, and that over two-thirds of these individuals are 
overweight or obese.  It is equally clear that excess adiposity and the subsequent 
elevation in systemic availability of fatty acid are causally linked with the development 
of insulin resistance in obesity.  Additionally, although exercise is known to be an 
important component of lifestyle programs aimed at improving obesity-related diseases, 
it is surprising that more is not known about the "dose" of exercise required to improve 
insulin sensitivity or the underlying mechanisms for this improvement.  For this reason 
the overarching purpose of my dissertation was to examine the effects of exercise and 
elevated fatty acid availability on insulin sensitivity and muscle lipid metabolism, and to 
determine whether altered muscle lipid metabolism is important for regulation of insulin 
sensitivity.  
 
Together, the three projects from my dissertation have fulfilled this purpose, and both 
individually and collectively provided insight regarding the effects of exercise and 
elevated fatty acid availability on muscle lipid metabolism and insulin sensitivity.  Most 
notably, these studies have: A) reported that a rather modest single session of exercise is 
sufficient to enhance insulin sensitivity in obese individuals, and that low intensity 
exercise may provide metabolic benefit that is equal (or perhaps enhanced) compared 
with moderate-to-high intensity exercise resulting in the same total energy expenditure 
(STUDY 2), B) affirmed that enhanced storage of excess fatty acid in muscle as 
triacylglycerol protects against accumulation of harmful lipid intermediates and impaired 
insulin sensitivity (STUDY 1 and STUDY 3), and, C) found that the saturation state of 




accumulation/partitioning or insulin signaling when provided a in a mixture of the most 
abundant fatty acids found in human plasma (STUDY 3).  Many other important details 
of each of my dissertation studies were described in Chapters 3-5, and thus will not be 
discussed in further detail here.  In this overall summary of my dissertation, I will attempt 
to expand on the findings of my projects, providing an integrative discussion of the 
collective significance and implications that can be derived from my dissertations studies, 
particularly as they relate to the working hypothesis of our laboratory. 
 
The key underlying component of all three of my dissertation studies was the 
examination of the hypothesis that "partitioning" excess fatty acid toward storage as 
triacylglycerol (TAG) in muscle cells may limit substrate for the accumulation of more 
harmful lipid intermediates (e.g., diacylglycerol [DAG], ceramide) and thereby protect 
against lipid-induced insulin resistance.  The basis for this hypothesis was largely 
generated from studies completed by a previous doctoral student in our laboratory, Simon 
Schenk, Ph.D.  Briefly, in his dissertation projects Dr. Schenk reported that a single 
session of rather vigorous exercise was sufficient to protect against lipid-induced insulin 
resistance in lean individuals, and that this protective effect of exercise was associated 
with a robust increase in muscle TAG content and attenuated muscle DAG and ceramide 
accumulation (compared with remaining sedentary).  Both STUDY 1 and STUDY 3 of 
my dissertation provide further support for this hypothesis.  In STUDY 1, I reported that 
an overnight (16h) lipid/heparin infusion after a single session of exercise resulted in a 
substantial (~30%) increase in muscle TAG content, but no increase in muscle DAG or 
ceramide content compared with an overnight saline infusion after exercise.  Importantly, 
despite the well documented negative effects of lipid infusion on insulin sensitivity, these 
subjects were (previously) shown to have no impairment in insulin sensitivity after the 
overnight lipid/heparin infusion compared with saline, suggesting that the preferential 
storage of excess lipid as TAG and limited accumulation of DAG and ceramide in muscle 
may have been important for this effect.  In STUDY 3, I found that, unlike the deleterious 
effects of 100% palmitate, mixtures of the five most abundant fatty acids in human 
plasma did not cause substantial impairment in insulin signaling in cultured muscle cells 




failure of these fatty acid mixtures to induce substantial impairment in insulin signaling 
was paralleled by very robust cellular TAG accumulation (>10-fold) but virtually no 
DAG accumulation, these findings also support the notion that preferential partitioning of 
excess fatty acid toward storage as TAG is protective against fatty acid-induced insulin 
resistance.  Conversely, the findings from STUDY 2 neither support nor refute our 
working hypothesis.  In STUDY 2, I reported that a rather modest single session of 
exercise was sufficient to enhance insulin sensitivity into the next day in obese adults, but 
did not find any changes in muscle lipid content (TAG, DAG, ceramide) that were 
associated with this effect.  Because I did not find an increase in muscle TAG content 
after exercise in this study, it is therefore not possible to evaluate our hypothesis 
concerning the beneficial effects of enhanced storage of excess fatty acid in muscle as 
TAG.  However, I must also acknowledge the possibility that “partitioning” of fatty acids 
among the major lipid pools may not be essential for the exercise-induced increase in 
insulin sensitivity in obesity.  This will be discussed in greater detail below.  Altogether 
the findings from my dissertation studies generally support
 
 the hypothesis that 
"partitioning" excess fatty acid toward storage as TAG in muscle cells may limit 
substrate for the accumulation of more harmful lipid intermediates (e.g., DAG, ceramide) 
and thereby protect against lipid-induced insulin resistance.  
Although my dissertation studies generally reaffirmed the major concepts of our working 
hypothesis, our previous suggestion that a single session of exercise acts to enhance the 
storage of fatty acid as intramyocellular TAG, and that an increase in the protein 
abundance of key TAG synthesis enzymes after exercise may be important for this effect 
was not as well supported.  In STUDY 1, I found that the increase in intramyocellular 
TAG accumulation after exercise when fatty acid availability was elevated was not 
accompanied by increased protein abundance of the TAG synthesis enzymes glycerol-3-
phosphate acyltransferase (GPAT) or diacylglycerol acyltransferase (DGAT).  However, 
because both of the experimental trials in this study required the participants to exercise 
(with the only difference between trials being the magnitude of fatty acid availability in 
the hours after exercise), it is certainly possible that exercise increased the abundance of 




did not further augment their abundance.  Nevertheless, in further contrast to our 
previous findings, I did not even find a significant increase in intramyocellular TAG 
content the day after either of the relatively modest exercise sessions performed by the 
participants in STUDY 2 of my dissertation (and similarly GPAT and DGAT protein 
abundance were also not affected).  This apparent discrepancy concerning the effect of 
exercise on muscle TAG accumulation between my current findings and previous work 
from our lab may be related to the much lower exercise stimulus used in my dissertation 
study, perhaps in combination with the fact the participants in my study were obese (Dr. 
Schenk's study used lean subjects exposed to an overnight lipid/heparin infusion), given 
that the large intramyocellular lipid pools in obesity may make detecting a relatively 
small (but potentially important) exercise-induced increase in TAG rather challenging.  
Nonetheless, even if exercise did induce a non-detectible increase in intramuscular TAG 
in my study, it was clear that this occurred in absence of an increase in GPAT or DGAT 
protein abundance.  Finally, although STUDY 3 of my dissertation did not incorporate 
exercise, findings from this study clearly demonstrated that an increase in GPAT and 
DGAT abundance was not required for cultured muscle cells to markedly increase TAG 
synthesis, resulting in more than a 10-fold increase in cellular TAG accumulation.  At 
this time, data concerning the notion that a single session of exercise acts to enhance the 
storage of fatty acid as intramyocellular TAG are somewhat equivocal, but it appears 
unlikely that an exercise-induced increase in GPAT or DGAT protein abundance is 
required for this effect. 
 
Much attention has been paid to the effects of different classes of fatty acids (e.g., 
saturated vs. unsaturated) as well as the species of fatty acid (e.g., palmitate vs. oleate) on 
metabolic health outcomes, including insulin resistance.  In contrast, our lab has 
generally placed emphasis on the deleterious consequences resulting from a general 
overabundance of fatty acid, rather than effects of specific fatty acids, per se.  Findings 
from STUDY 3 of my dissertation support the idea that the “amount” of available fatty 
acid may be a more important determinant of muscle cell lipid accumulation and insulin 
signaling than the “type” of available fatty acid.  In brief, in STUDY 3 I found that 




human plasma did not impair insulin signaling, even when the mixture contained a 
relatively high proportion of saturated fatty acids (60%; thus resembling or even 
exceeding the proportion of saturated fatty acids found in a very high saturated fat diet).  
Furthermore, accumulation of cellular TAG in response to the two different physiologic 
fatty acid mixtures was dose-dependent
 
, but virtually identical between the two mixtures 
at each specific dose of fatty acid.  And even though saturated fatty acids have previously 
been associated with increased muscle cell DAG accumulation, I found no increase in 
cellular DAG content in response to either mixture, at any dose of fatty acid exposure 
(including a fairly high physiologic plasma fatty acid concentration, 0.8mM).  These 
findings suggest that when muscle cells are exposed to the most abundant fatty acids 
found in human plasma in generally physiologic proportions and concentrations, even a 
marked difference in the proportion of saturated fatty acids in these mixtures (i.e., 60% 
vs. 40%,) may not be an important factor for determining the regulation of insulin 
signaling or lipid accumulation/partitioning within the cell.  Importantly, this should not 
be interpreted to suggest that the “type” of fatty acid may not have any influence on 
metabolic health outcomes (including insulin resistance), but rather that the overall effect 
of an increased abundance of fatty acids in our cultured C2C12 muscle cell model 
appeared to outweigh what may be subtle effects of (and deviations in) the various fatty 
acid classes/species that are typically found in humans. 
Several important questions that pertain to the findings from my dissertation studies 
remain unanswered.  Perhaps most intriguing, although my studies do support the 
hypothesis that that "partitioning" excess fatty acid toward storage as TAG in muscle 
cells may help to protect against lipid-induced insulin resistance, the mechanism(s) that 
may underlie enhanced fatty acid storage as TAG are still unknown.  Along these lines, 
though I was able to measure maximal in vitro GPAT and DGAT enzyme activity (and 
reported no changes in the activity of these enzymes) in STUDY 1, it is very important to 
note that this study did not allow me to capture the possible effect of exercise on the 
activity of these enzymes, and that these measurements may not reflect in vivo activity of 
these enzymes.  Thus, it remains both possible and likely that acute, modifiable 




TAG accumulation in my dissertation studies; however, such modifications (e.g., 
phosphorylation, acetylation) have not been well studied for these enzymes.  For this 
reason I propose conducting proteomic analysis of GPAT and DGAT isolated from the 
remaining muscle biopsy samples and cell homogenates of each of my dissertation 
studies.  These analyses would allow for detection of multiple forms of post-translational 
modification to these enzymes in response to exercise and/or elevated fatty acid 
availability, and even allow for comparisons between lean and obese individuals.  
Furthermore, if post-translational modifications to either or both of these enzymes were 
found to associate with changes in intramyocellular TAG accumulation, development of 
pharmacologic agents capable of modifying the activity of these enzymes may prove to 
be useful for clinical treatment and/or prevention of skeletal muscle insulin resistance. 
 
In summary, my dissertation studies support the notion that "partitioning" excess fatty 
acid toward storage as TAG in muscle cells may limit substrate for the accumulation of 
more harmful lipid intermediates (e.g., DAG, ceramide) and thereby protect against lipid-
induced insulin resistance.  These studies also reaffirm the importance and efficacy of 
exercise in the prevention and/or treatment of insulin resistance.  Specifically, I have 
shown that even a rather modest single session of exercise is sufficient to significantly 
improve insulin sensitivity into the next day in obese adults, and that low intensity 
exercise may provide metabolic benefit that is equal (or perhaps enhanced) compared 
with moderate-to-high intensity exercise resulting in the same total energy expenditure.  
Finally, I have found that the saturation state of fatty acids may not be an important factor 
for the regulation of muscle cell lipid accumulation/partitioning or insulin signaling, 
suggesting that the “amount” of available fatty acid may be a more important determinant 





















Intramyocellular Lipid Analysis 
 
 
The following is an outline of the procedure used to analyze intramyocellular lipid 
content in both STUDY 2 and STUDY 3 (Chapters 4 and 5, respectively).  In brief, these 
procedures describe total lipid extraction, isolation of the appropriate lipid fractions, and 
transmethylation methods used to ultimately determine triacylglycerol and diacylglycerol 
content in muscle biopsy samples and cultured C2C12 muscle cells using gas 
chromatography – mass spectrometry.  This method was developed in our laboratory by 
Alexander Hinko, Ph.D. 
 
A-1.   Total Lipid Extraction: Muscle Biopsies 
A-2.   Total Lipid Extraction: Myocytes  
B.   Isolation of the Total Lipid Extract 
C.   Solid Phase Extraction (SPE): 
a) Cholesterol Ester (CE) 
b) Triacylglycerol (TAG) 
c) Diacylglycerol (DAG) 
d) Monoacylglycerol (MAG) 
e) Non-esterified Fatty Acids (NEFA)  
f) Phospholipids (PL) 
D.   Transmethylation of the Fatty Acids of CE, TAG, DAG, MAG and PL by 
Alkaline Methanolysis, Yielding Fatty Acid Methyl Esters (FAMES) 
E.   Methylation of NEFA to Produce FAMES 
F.   Gas Chromatography - Mass Spectrometry (GCMS) of FAMES 




A-1.  Total Lipid Extraction: Muscle Biopsies 
1) Prepare solutionsa-d (see appendix) required for total lipid extraction, and make 
additions to microcentrifuge and extraction tubes (see steps 5 and 8) prior to 
homogenization. 
2) For each sample, rinse an all-glass homogenizer with methanol and air-dry 
3) Quickly weigh frozen muscle (~30 mg), then keep in dry ice until 
homogenization.  Homogenize frozen muscle in 1.0 ml of ice-cold 3.5% NaCla for 
~30 seconds, with the pestle attached to a motor drive rotating at 800 rpm.  Other 
components of the Western buffer are not used during homogenization due to 
possible lipid contaminants. 
4) Add 0.25 ml cold homogenate to a microcentrifuge tube already containing 0.2 ml 
of an incomplete Western bufferb at room temperature; quickly cap tube, vortex 
and place in ice. 
Notes: 
a) Components of the buffer may precipitate if the microcentrifuge tube is kept 
in ice prior to adding sample. 
b) Adding 0.25 ml of 3.5% NaCl (homogenate) completes the Western buffer. 
c) Pipet homogenate immediately after vortexing, before lipids begin to float. 
5) From this 0.45 ml volume, transfer 50 µl into an autoanalyzer vial with insert; 
store vial at -20°C for total protein assay (55.6% of original homogenate protein 
concentration). 
6) Centrifuge the remaining 0.4 ml of diluted homogenate at 15,000 x g for 10 
minutes at 4°C, then transfer the supernatant to a clean tube and store at -80°C 
(for Westerns). 
7) Add 0.6 ml of undiluted homogenate to a 16x125 mm glass screw-cap tube 
containing: 
a. 0.6 ml of a lipid marker mixc in chloroform (CHCl3)+10 µg/ml 
butylhydroxytoluene (BHT)d 
b. 1.65 ml additional CHCl3 + BHT 
c. 4.5 ml methanol (MeOH) 
d. 1.2 ml 3.5% NaCl 
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Also prepare duplicate blanks: omit homogenate; add 0.6 ml 3.5% NaCl in 
its place. 
CHCl3 - MeOH - aqueous ratio is 1 : 2 : 0.8, the single-phase lipid 
extraction ratio of Bligh & Dyer1  (i.e. 2.25 ml CHCl3 - 4.5 ml MeOH - 1.8 
ml aqueous saline). 
If some undiluted homogenate can still be recovered from the 
homogenizer, store this at -80°C for total protein assay.  The diluted 
homogenate (50 µl) can then be a "backup". 
8) Close extraction tube with PTFE-lined cap, vortex ~20 seconds, then allow to 
stand 1 hour at room temperature (or overnight at 4°C).  Proceed to section B. 
 
A-2.  Total Lipid Extraction: Myocytes 
1) Remove media from the myocyte culture dish, then rinse cells extensively with 
phosphate-buffered salinea. 
2) Remove the final rinse, then place dish on ice.  Add ~2.5 ml ice-cold 3.5% saline 
(if performing Westerns; see A-1) or a suitable buffer, then scrape cells while the 
dish rests on ice.  Quickly pipet aliquots, e.g. 3 x 0.8 ml, into microcentrifuge 
tubes kept in ice.  Proceed immediately to the next step, or store tubes at -80°C.  
Thaw cell lyzates in ice just prior to lipid extraction. 
3) Add 0.6 ml of lyzate to a 16x125 mm glass screw-cap tube that already contains: 
a. 0.6 ml of 6-lipid marker mix in CHCl3 + BHT 
b. 1.65 ml additional CHCl3 + BHT 
c. 4.5 ml MeOH 
d. 1.2 ml 3.5% NaCl 
Notes: a) Re-freeze remaining lyzate for protein assay 
b) Prepare duplicate blanks (0.6 ml of 3.5% NaCl instead of 
lyzate). 
4) Close extraction tube with PTFE-lined cap, vortex ~20 seconds, then allow to 





B.  Isolation of the Total Lipid Extract 
1) To separate lipids from polar molecules, first add 2.25 ml CHCl3, cap and vortex 
10 seconds, then add 2.25 ml H2O (order of addition reportedly affects yield).  
Re-cap tube and vortex vigorously ~30 seconds.   
CHCl3 - MeOH - aqueous ratio is now 2:2:1.8 (or 1:1:0.9), forming two phases. 
2) Centrifuge at 2,000 rpm (700 x g), for 5 min at room temp in the J-6B centrifuge 
to sharpen the interface.  Slow the rotor gradually (brake setting = 4). 
upper phase: methanol + H2O + polar compounds, but virtually no lipid 
interface: de-lipidated protein precipitate; forms a compacted disk 
lower phase: chloroform + lipids 
3) Using an aspirator flask and a 9" glass pipet as the suction tip, remove and discard 
nearly all of the upper phase.  With practice, the protein interface disk can also be 
aspirated with little or no loss of lower phase.  Residual upper phase forms a ring 
around exposed chloroform in the center of the surface. 
4) Using a 9" glass pipet with manual pump, insert the tip through the central 
chloroform surface down to the tube bottom.  Draw up the lower phase and 
transfer to a 13x100 mm glass screw-cap tube.  Leave behind a droplet of lower 
phase to keep the tip isolated from residual protein precipitate or upper phase. 
Note: More than one draw is necessary.  Watch the level in the pipet to avoid 
overfilling. 
5) Cap the tube containing the total lipid extract, and store at -20oC until lipid 
separation by SPE (Solid Phase Extraction) (section C). 
 
C.  Solid Phase Extraction (SPE): 
a) Cholesterol Ester (CE)  
b) Triacylglycerol (TAG)  
c) Diacylglycerol (DAG)  
d) Monoacylglycerol (MAG)  
e) Non-esterified Fatty Acids (NEFA) 




1) Begin dry-down of total lipid extracts, using speed-vac without heat (1.5 - 2.0 
hours), then prepare elution solvent mixturesf-i. 
2) Clean vacuum chamber ports of polar contaminants: 
a. attach an empty column or syringe barrel to the port  inlet, and place a 
waste tube in the vacuum chamber beneath the outlet, and 
b. add ~3 ml MeOH, then draw this through using vacuum. 
3) Equilibrate NH2-SPEe cartridge columns with hexane: 
a.  attach NH2-SPE column to a MeOH-cleaned port, add ~2 ml hexane, and 
draw through until the hexane surface is just above the upper frit, 
b. add another 2 ml hexane, draw down halfway to the frit, then 
c. allow column to equilibrate in hexane at least 20 minutes. 
Note: Hexane also cleans the ports of non-polar contaminants. 
4) Reconstitute each dried lipid extract in 100 µl CHCl3; gently swirl to dissolve 
lipids. 
Note:-Unlike hexane, CHCl3 is a solvent for lipids of widely varying polarity. 
5) Draw down the hexane until surface is just above frit, then replace the waste tube 
with a 13 x 100 mm glass screw-cap tube (fraction tube #1). 
6) Using a gel-loading pipet tip and pipetter adjusted to slightly greater than 100 µl, 
transfer as much of the lipid sample as possible directly into the hexane above the 
frit, then draw down the sample slowly until the surface just reaches the frit. 
Notes: 
a. Do not expose the top of the resin bed to air. 
b. Do not increase the CHCl3 addition to the column above 100 µl, or the 
hexane equilibrium may become altered. 
c. Fraction tubes 2 through 7 are also 13 x 100 mm glass screw-cap. 
7) Add 2.0 ml hexane (no splashing), draw down to the frit, then repeat with two 
additional 2.0 ml hexane volumes. 
Tube #1 now contains purified CE in ~6 ml collected hexane. 
8) Insert tube #2 and elute with 2 x 2.0 ml of 15.5% ethyl acetate (EtOAc) in 
hexanef. 
Tube #2 contains most or all of the TAG in 4.0 ml. 
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9) Insert tube #3 and elute with 2.0 ml of 15.5% EtOAc in hexane. 
10) Insert tube #4 and elute with 2.0 ml of 15.5% EtOAc in hexane. 
Note: Tubes 3 & 4 contain transition fractions: the tail of TAG and the leading 
edge of DAG, respectively.  Collecting two small, successive volumes reduces the 
chance of TAG contaminating the bulk of DAG. 
11) Insert tube #5 and elute with 2 x 2.0 ml volumes of 15.5% EtOAc in hexane. 
Tube #5 contains most/all of the DAG in 4.0 ml. 
12) Insert tube #6 and elute with 2 x 2.0 ml of 15.5% EtOAc in hexane. 
This is an "insurance" tube for DAG if retention is unusually strong. 
13) Insert tube #7 and elute with 3 x 2.0 ml of CHCl3 - MeOH (23:1)g. 
Tube #7 contains MAG in 6.0 ml. 
Note: The following tubes 8, 9 and 10 are 16 x 125 mm glass screw-cap. 
14) Insert tube #8 and elute with 3 x 2.0 ml of diisopropyl ether - acetic acid (98:5)h. 
Tube #8 contains NEFA in 6.0 ml. 
15) Insert tube #9; elute with 2x2.0 ml of CHCl3-MeOH-3.6M ammonium acetate 
(30:60:8)i. 
Tube #9 contains PL in 4.0 ml. 
Note:-Do not collect PL in a fraction larger than 4.0 ml, or the solvent volumes 
subsequently needed for PL extraction may collectively exceed the capacity of the 
fraction tube (see PL extraction below). 
16) Insert tube #10 and elute with 2x2.0 ml of CHCl3-MeOH-3.6M ammonium 
acetate. 
This is the PL "insurance" fraction. 
17) Dry down tubes 1, 2, 5,7 and 8 in the speed-vac w/o heat, then reconstitute 1, 2, 5 
and 7 (not 8) with 200 µl toluene.  Transfer 40 µl to a plain 13 x 100 mm tube for 
alkaline methanolysis.  Re-cap remaining 160 µl and store at -20°C. 
The primary purpose of the small aliquot is to determine the purity of each 
fraction. 
If there is contamination indicated by the FAMES from internal standard markers, 
the remaining 160 µl can be dried, reconstituted in CHCl3, and re-
chromatographed on a clean NH2-SPE cartridge using freshly made elution 
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solvents.  The most likely cause of poor SPE is incorrectly prepared elution 
solvent mixtures.  However, if fractions are well-purified, then results for 
abundant lipids, e.g. TAG, may be obtainable from the small aliquot.  However, 
scarce lipids such as DAG require processing the remaining 160 µl, and the final 
FAME prep from this may have to be combined with that from the aliquot, dried, 
then reconstituted in 40 µl for GCMS. 
Note: Do not attempt to dry down tube #9.  The large amount of ammonium 
acetate in this fraction necessitates first extracting PL, to separate it from the 
ammonium acetate, prior to dry down. 
18) Extraction of PL in tube #9: 
Since the solvent composition (3 components) of this fraction is CHCl3 = 1.225 
ml, MeOH = 2.45 ml, aqeous ammonium acetate = 0.327 ml, then 1.225 ml 
CHCl3 and 1.878 ml H2O should be added to obtain CHCl3 = 2.45 ml, MeOH = 
2.45 ml, aqeous = 2.205 ml (1 : 1 : 0.9). 
This forms two-phases, with [CHCl3 + PL] as the lower phase. 
19) Isolate and dry down the lower phase (same procedure as for total lipid 
extraction). 
20) Reconstitute with 200 µl toluene and transfer 40 µl to a plain 13 x 100 mm glass 
tube for alkaline methanolysis.  Re-cap the remaining 160 µl and store at -20°C. 
 
D.  Transmethylation of the Fatty Acids of CE, TAG, DAG, MAG and PL by 
Alkaline Methanolysis, Yielding Fatty Acid Methyl Esters (FAMES) 
Alkaline methanolysis only affects ester bonds linking fatty acids to an alcohol, such as 
glycerol or cholesterol.  Under conditions of basic pH, presence of methanol and absence 
of water, fatty acids are transmethylated, i.e. methanol replaces the original alcohol, to 
produce FAMES.  This procedure neither methylates NEFA, nor transmethylates fatty 
acids incorporated by amide bonds in sphingolipids, which may be present in some of the 
SPE fractions. 
1) To each aliquot of 1, 2, 5, 7 and 9, add 1.0 ml of 0.2 N sodium hydroxide (NaOH) 




2) Neutralize reaction by adding 0.9 ml of 1.0 M sodium acetate buffer, pH 4.75k 
and vortexing.  Add 1.0 ml CHCl3 and vortex.  Obtain and dry down the lower 
phase.  
Lower phase = [CHCl3 + lipid-derived FAMES] 
3) Reconstitute in 40 µl heptane and transfer to poly-spring inserts in crimp-seal 
autoanalyzer vials.  Tightly cap and store at -20°C until GCMS. 
 
E.  Methylation of NEFA to Produce FAMES 
An iodomethane (methyl iodide) method is used to methylate NEFA to form FAMES.  
This method does not transmethylate, so FAMES obtained with iodomethane originate 
solely from NEFA. 
1) Reconstitute tube #8 in 200 µl MeOH, transfer 40 µl to a 16 x 125 mm glass 
screw-cap tube and dry down.  Re-cap the remaining 160 µl and store at -20°C. 
2) To the aliquot, add 250 µl of 0.2 M phosphate/TBA buffer, pH 9.0l, and also 250 
µl of 10% iodomethane in dichloromethanem.  Cap and vortex vigorously for 1 
hour at room temperature using a platform shaker. 
3) Add 3.0 ml hexane, re-cap tube and vortex vigorously ~30 seconds.  Centrifuge in 
the J-6B as described in section B, to sharpen the interface between the large 
upper phase (organic solvents + FAMES) and the small, aqueous lower phase. 
4) Using a glass pipet and pipet pump, transfer the upper phase to a 13 x 100 mm 
plain tube.  Leave behind a small amount of upper phase to decrease the chance of 
removing some lower phase.  Dry the upper phase in speed-vac without heat. 
5) Reconstitute in 200 µl heptane, then transfer 40 µl to a polyspring insert in a 
crimp-seal vial.  Cap and store at -20°C until GCMS.  Cap the remaining 160 µl 
and also store at -20°C.  NEFA will be scarce in muscle biopsies, but abundant in 
myocytes treated with exogenous fatty acids.  After verifying purity, the 
remaining 160 µl will have to be processed for NEFA for biopsies, but not for 
fatty acid-treated myocytes.  However, it may be necessary to process the larger 





F.  Gas Chromatography - Mass Spectrometry (GCMS) of FAMES 
Refer to the FAMES program in the Agilent instrument software which controls the 
GCMS. 
 
G.  Solutions and Reagents 
a) 3.5% NaCl = 3.5 g NaCl / 100 ml ultrapure H2O (Fisher cat# W6-4)  
  (NaCl, SigmaUltra = Sigma cat# S7653)   
        phosphate-buffered saline (PBS), pH 7.4:  10x solution (Sigma cat# PS493) 
    dilute to 1x with ultrapure 
H2O 
       b) Western buffer: adapted from Dr. Minghua Li, personal communication   
        Note: adding 250 µl sample (in 3.5% saline) completes buffer  
           per sample e.g. for 
"10" 
samples 
     (actual 8 
samples) 
    µl µl 
 1) NP-40 (density = 1.065 g / ml) 4.5 45 
       
 2) 1.0 M tris-HCl, pH 7.4  10 100 
       
 Combine 1 and 2: first weigh 4.8 g NP-40 (4.5 ml) into a tared scintillation 
vial. 
 Add 10.0 ml of tris-HCl, cap and mix thoroughly end-over-end; let stand 
until 
 bubbles dissipate.  Slowly take up and dispense 145 µl per 10 samples.  
       
 3) 0.5 M sodium fluoride (NaF) 20 200 
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 4) 0.1 M EDTA, pH 8.0  11.2 112 
       
 5) 0.1 M sodium pyrophosphate (NaPP) 13 130 
       
 6) 1.0 M β-glycero-phosphate 10 100 
       
 7) 55.6% glycerol  90 900 
       
 8) 60 mM Perfabloc  5 50 
       
 9) complete mini  32.3 323 
       
 10) PIC 2   2 20 
       
 11) PIC 3   2 20 
       
 total volume of incomplete buffer 200 2,000 
      
 12) sample in 3.5% NaCl  250   
      
 final volume   450   
       
 preparation of buffer components:    
       
 1) NP-40, pure use as shipped   
       
 2) 1.0 M tris-HCl, pH 7.4 mw 157.6 1.0 M = 15.76 g / 100 ml 
H2O 
       
 3) 0.5 M NaF mw 41.99 0.5 M = 2.1 g / 100 ml 
H2O 
 
       




     (tetrasodium dihydrate)     
       
 5) 0.1 M NaPP mw 446.06 0.1 M = 4.46 g / 100 ml 
H2O 
     (tetrabasic decahydrate)     
       
 6) 1.0 M beta-glycero- mw 216.04 1.0 M = 21.6 g / 100 ml 
H2O 
     phosphate, disodium     
       
 7) 55.6% glycerol density of pure glycerol = 1.264 g / ml  
   55.6%  = 70.28 g glycerol + 44.4 ml H2O 
       
 8) 60 mM Perfabloc mw 239.5 60 mM = 14.37 mg / ml 
H2O 
   (Roche; proprietary protease inhibitor)  
       
 9) complete mini one tablet dissolved in 1.8 ml H2O; use 
4-ml 
     (EDTA-free) glass vial with PTFE-lined cap   
   (Roche; proprietary protease inhibitor)  
       
 10) PIC 2  use as shipped; bring to room temp to 
melt 
   DMSO (Sigma; phosphatase inhibitor 
mix) 
       
 11) PIC 3  use as shipped; bring to room temp to 
melt 
   DMSO (Sigma; phosphatase inhibitor 
mix) 
       
c) six odd C# lipid marker standards in CHCl3 + 10 µg / ml BHT (d):  
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 1) [C13:0] - Cholesteryl Tridecanoate (CE)   
  Nu-Chek cat# CH-812 mw 583.08   
  3.0 mM stock solution    
  0.15 mM working solution (15.0 nmol / 100 µl)  
       
 example: 1.0 mM = 583.08 mg / liter = 58.308 mg / 100 ml  
  3.0 mM stock = 174.924 mg / 100 ml   
  3.0 mM = 129 mg weighed / 73.75 ml solvent  
  0.15 mM = 2.0 ml stock +38.0 ml solvent   
            
 2) [C15:0] - Dipentadecanoin (DAG)   
  Nu-Chek cat# D-146 mw 540.88   
  1.5 mM stock solution    
  0.015 mM working solution (1.5 nmol / 100 µl)  
       
 example: 1.0 mM = 540.88 mg / liter = 54.088 mg / 100 ml  
  1.5 mM stock = 81.132 mg / 100 ml   
  1.5 mM = 130 mg weighed / 160.233 ml solvent  
  0.015 mM = 0.5 ml stock + 49.5 ml solvent   
            
 3) [C17:0] - Heptadecanoic Acid (NEFA)   
  Nu-Chek cat# N-17-A mw 270.48   
  3.0 mM stock solution    
  0.15 mM working solution (15.0 nmol / 100 µl)  
       
 example: 1.0 mM = 270.48 mg / liter = 27.048 mg / 100 ml  
  3.0 mM stock = 81.144 mg / 100 ml   
  3.0 mM = 115 mg weighed / 141.723 ml solvent  
  0.15 mM = 2.0 ml stock + 38.0 ml solvent   
            
151 
 
 4) [C19:0] - Monononadecanoin (MAG)   
  Nu-Chek cat# M-169 mw 372.51   
  3.0 mM stock solution    
  0.03 mM working solution (3.0 nmol / 100 µl)  
       
 example: 1.0 mM = 372.51 mg / liter = 37.251 mg / 100 ml  
  3.0 mM stock = 111.753 mg / 100 ml   
  3.0 mM = 125 mg weighed / 111.85 ml solvent  
  0.03 mM = 0.5 ml stock + 49.5 ml solvent   
            
       
            
 5) [C21:0]-Diheneicosanoyl-glycero-phosphocholine (PL)  
  Avanti cat# 167397 mw 874.32   
  1.5 mM stock solution    
  0.75 mM working solution (75.0 nmol / 100 µl)  
       
 example: 1.0 mM = 874.32 mg / liter = 87.432 mg / 100 ml  
  1.5 mM stock = 131.148 mg / 200 ml   
  1.5 mM = 104 mg weighed / 158.60 ml solvent  
  0.75 mM = 25.0 ml stock + 25.0 ml solvent   
            
 6) [C23:0] - Tritricosanoin (TAG)   
  Nu-Chek cat# T-185 mw 1101.88   
  5.0 mM stock solution    
  1.0 mM working solution (100.0 nmol / 100 µl)  
       
 example: 1.0 mM = 1101.88 mg / liter = 110.188 mg / 100 ml  
  5.0 mM stock = 550.94 mg / 100 ml   
  5.0 mM = 296 mg weighed / 53.726 ml solvent  
  1.0 mM = 10.0 ml stock + 40.0 ml solvent   
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 preparation of the 6-lipid marker mix:     
       
  combine 100 µl of each working solution for each   
  sample or blank, e.g. for 10 samples, combine 1.0 ml of  
  each working solution (6 ml total volume)    
       
  when 0.6 ml mixture is added to each sample, the   
  following amounts are added:   
       
  [C13:0] CE  15.0 nmol   
  [C15:0] DAG  1.5 nmol   
  [C17:0] NEFA  15.0 nmol   
  [C19:0] MAG  3.0 nmol   
  [C21:0] PL  75.0 nmol   
  [C23:0] TAG  100.0 nmol   
       
  at the end of sample processing, if recovery is 100% for  
  each lipid marker in a pure fraction, then the maximum  
  amounts of the following fatty acid methyl esters   
  (FAMES) derived from the markers would be:  
  C13:0ME  15.0 nmol   
  C15:0ME  3.0 nmol   
  C17:0ME  15.0 nmol   
  C19:0ME  3.0 nmol   
  C21:0ME  150.0 nmol   
  C23:0ME  300.0 nmol   
       
d) BHT = 3,5-Di-tert-butyl-4-hydroxytoluene Supelco 
cat# 44-
2377 
 (acts as an anti-oxidant; protects double bonds)   
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 BHT stock solution (50x) = 500 µg / ml CHCl3 (0.5 mg / ml)  
 20 ml stock solution + 980 ml CHCl3 = 10 µg BHT / ml CHCl3  
       
e) aminopropyl SPE tubes, Supelco cat#57014, 500 mg bed, 3 ml volume  
       
f) ethyl acetate - hexane (15.5 : 84.5, v/v) = 124 ml ethyl acetate + 676 ml 
hexane 
       
g) CHCl3 - MeOH (23 : 1, v/v) = 460 ml chloroform + 20 ml methanol  
       
h) diisopropyl ether - acetic acid (98 : 5, v/v) =    
  392 ml diisopropyl ether + 20 ml acetic acid   
       
i) CHCl3 - MeOH - 3.6 M ammonium acetate (30 : 60 : 8, v/v/v) =   
 150 ml chloroform + 300 ml methanol + 40 ml 3.6 M ammonium acetate 
       
 Note: Ammonium acetate 7.5 M solution (Sigma cat# A2706).  
  3.6 M = 96 ml of 7.5 M + 104 ml H2O    
  Store 7.5 M and 3.6 M solutions at 4°C.   
       
j) 0.2N NaOH in methanol:    NaOH mw = 40  
       
  1.0 N NaOH = 40 g / liter    
  0.2 N NaOH = 8 g / liter = 2 g / 0.25 liter = 2 g / 250 ml 
MeOH 
       
 Note: Some sodium carbonate (fine white particulate) forms when 
  dissolving NaOH in MeOH.  Allow the sodium carbonate  
  to settle, then take aliquots from near the top.   
       
k) 1.0 M sodium acetate buffer, pH 4.75:           
  glacial acetic acid mw = 60.05   




1) dissolve 68 g sodium acetate trihydrate in ~800 ml H2O in a 1-liter beaker 
 
2) add 30 g glacial acetic acid while stirring (this pure liquid is weighed);  
     rinse the weigh boat into the beaker with several small volumes of H2O 
 3) check the pH; it should be approximately 4.75   
 4) pour into a 1-liter graduated cylinder and rinse beaker into the cylinder 
 5) bring the volume to 1 liter with H2O, then carefully drop in a stirring bar  
      and mix until solution is uniform    
       
l) 0.2 M phosphate/TBA buffer, pH 9.0:    
  potassium phosphate, dibasic mw = 174.18   
  tetrabutylammonium hydrogen sulfate (TBA) mw = 339.53  
       
 dissolve 34.8 g (0.2 mol) K2HPO4 and 16.98 g TBA (0.05 mol) in~800 ml 
 H2O, then adjust pH to 9.0 and bring volume to 1 liter as in (k)  
       
m) 10% (v/v) iodomethane in dichloromethane =   








Cell Culture Methodology 
 
 
The following is an outline of the basic cell culture methodology used to complete 
STUDY 3 (Chapter 5).  Part A of this appendix serves as a summary of the step-by-step 
details of the procedures used to grow, plat, split/passage, freeze, and differentiate C2C12 
myoblasts.  These methods were developed by Sean Alec Newsom with guidance from 
Christopher L. Mendias, Ph.D.  Part B of this appendix provides a brief outline of the 
protocol used to complete experiments for STUDY 3.  This protocol was developed by 
Sean Alec Newsom.   
 
Part A: Summary of basic cell culture methodology 
Growing and Splitting Cells 
Growth Media 
1. From a volume of 500 mL (total volume) of DMEM High Glucose, remove 55 mL 
(11% of total volume).  
2. Add 5 mL (1% of total volume) of Anti-Biotic, Anti-Mycotic (ABAM-aliquots stored 
in the -20 °C freezer). 
3. Add 50 mL (10% of total volume) of Fetal Bovine Serum (FBS-aliquots stored in the 
-20 °C freezer).  
 
Plating Cells 
1. Remove growth media from the refrigerator and warm to 37 °C in water bath. After 
media has warmed, remove cryo vials of cells from liquid nitrogen and thaw in water 
bath at 37 °C.   
2. After the cells are thawed, pipette each cryo vial of cells into 15 mL Falcon Tubes.  
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3. Dilute the cells with at least 10 mL of growth media per Falcon Tube. Rinse cryo vial 
with growth media.   
4. Centrifuge for 5 min at 2000 rpm.  
5. Add approximately 4 mL of growth media to each cell dish.  
6. Remove the supernatant from each Falcon Tube and dispose in the waste container. 
Do not hit the cells!  
7. Add approximately 4 mL (want a total volume of about 8 mL per dish) of growth 
media to the cells and mix by rinsing pipette multiple times to break up pellet at the 
bottom. Make sure that all cells are broken apart from pellet and no clusters of cells 
can be seen. 
8. Add the cell/media mixture to each dish and very gently shake the dish 
(forward/backward and side/side, do not shake in a circle).  
9. Label the plates with your name, date, and pass (this is pass 0 or P0). Put the cell 
dishes in the incubator at 37 °C.  
 
Splitting Cells 
1. Take growth media and trypsin out of the refrigerator.  Place the growth media in the 
water bath (at 37 °C) and allow the trypsin to warm to room temperature. 
2. Remove cells from incubator and check under microscope to ensure that cells grew 
(confluence ≥ 70%). 
3. Tip the plate to one side and remove the growth media (which also contains the dead 
cells). Be sure not to touch the bottom of the plate with the waste pipette.  
4. Gently add 4 mL of DPBS to the side of the dish and rinse the cells.  Remove DPBS 
similarly to removing growth media (step 3).  
5. Add about 4 mL of Trypsin (.25%).  Can be slightly more aggressive since this is 
used to detach the cells from the bottom of the dish. 
6. Put cells with trypsin in incubator for approximately 5 min. 
7. Remove the cell dishes from the incubator.  Using the microscope, check to see that 
the cells are detached (should see the cells floating when the plate is moved slightly). 
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8. Add approximately 9 mL of growth media to the dish and rinse the dish multiple 
times. To rinse, tip the plate, pipette the media and thoroughly rinse the rest of the 
plate.  
9. Move the media/cell mixture(s) into 15 mL Falcon Tube(s). 
10. Centrifuge for 5 min at 2000 rpm. 
11. Add approximately 4 mL of growth media to each plate.  
12. Remove supernatant of trypsin/media from Falcon Tube(s) and put in waste 
container. Do not hit the cells! 
13. Add approximately 4 mL (want a total volume of about 8 mL per dish) of growth 
media to each falcon tube (add enough for 4 mL per plate!) and mix by rinsing the 
pipette multiple times to break up the pellet at the bottom. 
14. Take out total volume and evenly distribute between dishes (4mL per plate). When 
adding to the dish, lightly drop the volume (4mL) evenly throughout the plate. 
15. Label the plates with your name, the date and the pass. Incubate the dishes at 37 °C. 
 
Freezing Cells – Using non-differentiated cells only 
1. Take growth media and trypsin out of the refrigerator.  Place the growth media in the 
water bath (at 37 °C) and allow the trypsin to warm to room temperature. 
2. Remove cells from incubator and check under microscope to ensure that cells grew 
(confluence ≥ 70 °C). 
3. Tip the plate to one side and remove the growth media (which also contains the dead 
cells).  Be sure not to touch the bottom of the plate with the waste pipette. 
4. Gently add 4 mL of DPBS to the side of the dish and rinse the cells.  Remove DPBS 
similarly to removing growth media (step 3).  
5. Add about 4 mL of Trypsin (.25%).  Can be slightly more aggressive since this is 
used to detach the cells from the bottom of the dish. 
6. Put cells with trypsin in incubator for approximately 5 min. 
7. While waiting for cells to incubate, make freezing media (10 % DMSO in growth 
media). Make enough for about 1 ½ mL per cryo vial of cells (for one cryo vial add 
150µL DMSO to 1350µL growth media) 
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8. Remove the cell dishes from the incubator.  Using the microscope, check to see that 
the cells are detached (floating). 
9. Add approximately 9 mL of growth media and rinse the dish multiple times. To rinse, 
tip the plate, pipette the media and thoroughly rinse the rest of the plate.  
10. Move the media/cell mixture(s) into 15 mL Falcon Tube(s). 
11. Centrifuge for 5 min at 2000 rpm. 
12. Remove supernatant of trypsin/media from Falcon Tube(s) and put in waste 
container. Do not hit the cells!  
13.  Add approximately 1 ½ mL of freezing media (10% DMSO in growth media).  Mix 
by rinsing the pipette multiple times to break up the pellet at the bottom. 
14. Move mixture into labeled cryo vial (label with date cells were frozen and name).   
15. Put cryo vials of cells into Mr. Frosty for about 24 hours. 




1. From a volume of 500 mL (total volume) of DMEM High Glucose, remove 15 mL 
(3% of total volume).  
2. Add 5 mL (1% of total volume) of Anti-Biotic, Anti-Mycotic (ABAM-aliquots stored 
in the -20 °C freezer). 




1. Take differentiating media out of the refrigerator and warm in water bath to 37 °C. 
2. Remove cells from incubator and check under microscope to ensure that cells grew 
(confluence ≥ 70 °C). 
3. Tip the plate to one side and remove the growth media (which also contains the dead 
cells).  Be sure not to touch the bottom of the plate with the waste pipette. 
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4. If cells have confluence ≥ 90%, remove all growth media and rinse with DPBS.  
Otherwise, there can be a little bit of growth media in the dish but still remove as 
much of the growth media as possible.  
5. Add differentiating media to each dish/well by tipping the plate and gently adding it 
to the side.  
6. Label the dish with the date the cells were differentiated. Incubate the dishes at 37 °C. 
 
 
Part B: Example experiment guide 
All cells used in these experiments were P3 at point of differentiation!!! 
Cell Growth 
Media: HG-DMEM + 10% FBS + 1% AbAm 
Plastic: 100mm Tissue Culture Treated Plates 
Passage: 16-20h 
For final passage prior to differentiation, move to 6-well plates: 
Plastic: 6x35mm (6-well) Tissue Culture Treated Plates 
- One 100mm plate at ~80% confluence suspended in 40mL 
- Take 2mL/well (no pre-coating of plate) 
 
Differentiating Cells 
Media: HG-DMEM + 2% HS + 1% AbAm, changed every 48h 
Plastic: 2x(6x35mm; 6-well) Tissue Culture Treated Plates 
- Cells should be ready for differentiation media 20-24h after seeding 
- Cells were differentiated for 4.5d before switching to low glucose media 
 
TIMES LISTED BELOW REPRESENT HOURS PRIOR TO INSULIN TREATMENT 
 
12h: Switch to LG-DMEM + 1% AbAm + 2% BSA ± FA 
Solutions needed: 
‐ LG-DMEM + 1% AbAm + 2% FAF-BSA + EtOH (CON) 
‐  LG-DMEM + 1% AbAm + 2% FAF-BSA + 0.1mM FA 
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‐ LG-DMEM + 1% AbAm + 2% FAF-BSA + 0.2mM FA 
‐ LG-DMEM + 1% AbAm + 2% FAF-BSA + 0.4mM FA 
‐ LG-DMEM + 1% AbAm + 2% FAF-BSA + 0.8mM FA 
Directions: 
Final FA mixture concentrations desired: 0.1, 0.2, 0.4, 0.8mM 
‐ Stock = 160mM (200x for 0.8mM), therefore serially dilute w/ EtOH for other 
concentrations 
‐ Will need 10uL/2mL of media 
‐ Be sure to make CON solution with 10uL EtOH/2mL media 
 
0h: 15min incubation ± Insulin 
Solutions needed: 
‐ 200x Stock (20uM) is prepared 
Directions: 
Insulin concentration desired: 100nM 
‐ Add 10uL/2mL media 
 
Cell Lysis for Westerns 
1) 2x Rinse w/ cold DPBS 
2) Add 125μL cold lysis buffer and lightly rotate in fridge for >5min  
3) Scrape plate thoroughly, place on ice when not being scraped 
4) Repeatedly mix sample using P1000 to ensure homogenization 
5) Place homogenate in 1.5mL eppendorf tube 
6) Centrifuge at 15k-rpm for 10min at 4C using bench-top centrifuge 
7) Collect supernatant, run protein assay and/or place in -80C 
  
 
